[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 111
1. Wen YC, Wu HH, Chen KK: Pan-urethral wart treated with 5-fluorouracil intraurethral instillation. J Chin Med Assoc; 2006 Aug;69(8):391-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pan-urethral wart treated with 5-fluorouracil intraurethral instillation.
  • Cystourethroscopy on the following day showed extensive wart lesions extending from the urethra to the bladder neck.
  • After 18 doses of 5-FU solution urethral instillation, no visible wart lesions were noted.
  • [MeSH-major] Fluorouracil / administration & dosage. Urethral Diseases / drug therapy. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Urethral Disorders.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970277.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Barbaud A, Reichert-Penetrat S, Trechot P, Granel F, Schmutz JL: [Sensitization to resorcinol in a prescription verrucide preparation: unusual systemic clinical features and prevalence]. Ann Dermatol Venereol; 2001 May;128(5):615-8
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Lorraine, where it is used in high concentrations in an anti-wart ointment, this molecule has induced many cases of allergy.
  • Contact sensitization was found in 24 patients, who all but one had previously used the anti-wart ointment containing resorcinol.
  • All developed contact eczema on the site of application of the ointment, with generalized urticaria (4 cases), pompholyx (1 case), and generalized papulo-vesicular rash with pompholyx (6 cases).
  • [MeSH-major] Dermatitis, Contact / epidemiology. Dermatitis, Contact / etiology. Drug Eruptions / epidemiology. Drug Eruptions / etiology. Drug Hypersensitivity / epidemiology. Drug Hypersensitivity / etiology. Eczema / chemically induced. Eczema / epidemiology. Resorcinols / adverse effects. Warts / drug therapy
  • [MeSH-minor] Administration, Cutaneous. France / epidemiology. Humans. Incidence. Ointments. Patch Tests. Population Surveillance. Prevalence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11427795.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Ointments; 0 / Resorcinols
  •  go-up   go-down


3. Hoyme UB, Hagedorn M, Schindler AE, Schneede P, Hopfenmüller W, Schorn K, Eul A: Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol; 2002;10(2):79-88
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
  • OBJECTIVES: Imiquimod is an immune response modifier that has demonstrated a good efficacy and relatively low recurrence rates in comparison to other genital wart treatment modalities.
  • The primary objective of this open-label study was to evaluate the effect on sustained clearance of treated lesions and the safety of patient-applied topical imiquimod after laser therapy of external anogenital warts.
  • METHODS: After laser treatment of visible external anogenital warts the ablated region(s) were treated with imiquimod 5% cream three times/week over 12 weeks beginning when the wound healing process was completed, followed by a six-month treatment-free observation period for the assessment of sustained clearance of treated lesions.
  • After 12 weeks of treatment, 65.4% of all patients showed sustained clearance.
  • During the treatment period, 15 patients (7.1% of 211 patients) presented with recurrent warts in the treated areas, and 58 (27.5%) patients were excluded for other reasons.
  • During the six-month follow-up period, ten additional patients (7.3% of 138 patients) developed wart recurrences.
  • The number of patients with adverse events related to study medication declined from the first month of treatment until the end of the third month.
  • CONCLUSIONS: After laser therapy and sufficient wound healing, administration of imiquimod 5% cream three times/week appears to be safe and to reduce the incidence of wart recurrences.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Condylomata Acuminata / drug therapy. Condylomata Acuminata / surgery. Laser Therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Patient Compliance. Patient Dropouts. Prospective Studies. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • [Cites] Int J STD AIDS. 2001 Jan;12(1):22-8 [11177478.001]
  • [Cites] Eur J Med Res. 2000 Aug 18;5(8):347-55 [10958768.001]
  • [Cites] Br J Dermatol. 2000 Jul;143(1):59-65 [10886136.001]
  • [Cites] J Infect Dis. 1998 Aug;178(2):551-5 [9697742.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):25-30 [9449906.001]
  • [Cites] Am J Med. 1997 May 5;102(5A):3-8 [9217656.001]
  • [Cites] Surgery. 1997 Apr;121(4):440-8 [9122875.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):768-74 [7801889.001]
  • [Cites] Obstet Gynecol. 1989 Jan;73(1):25-30 [2535764.001]
  • [Cites] Urology. 1987 Jun;29(6):608-10 [3576886.001]
  • [Cites] Int J Immunopharmacol. 1999 Jan;21(1):1-14 [10411278.001]
  • [Cites] N Engl J Med. 1985 Sep 26;313(13):784-8 [2993887.001]
  • [Cites] Inflammation. 1998 Dec;22(6):619-29 [9824775.001]
  • (PMID = 12530484.001).
  • [ISSN] 1064-7449
  • [Journal-full-title] Infectious diseases in obstetrics and gynecology
  • [ISO-abbreviation] Infect Dis Obstet Gynecol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Other-IDs] NLM/ PMC1784609
  •  go-up   go-down


Advertisement
4. Moore RA, Edwards JE, Hopwood J, Hicks D: Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis; 2001;1:3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod for the treatment of genital warts: a quantitative systematic review.
  • OBJECTIVE: To review published randomised controlled trials to assess the benefit and harm of imiquimod in the treatment of external genital warts.
  • Relative benefit and number needed to treat were calculated for the main outcomes of wart clearance at the end of therapy, of at least 50% reduction in wart area, and of complete clearance at the end of treatment and no recurrence of warts during a follow-up period, as well as for adverse effect withdrawal or lack of efficacy withdrawal.
  • In five trials with HIV-negative patients complete clearance of warts at the end of treatment occurred in 51% of patients treated with imiquimod 2% or 5% cream and 6% of placebo treated patients.
  • In four trials at least 50% wart area reduction occurred with 72% of patients treated with imiquimod 5% cream and 20% of placebo treated patients.
  • In three trials complete clearance of warts at the end of treatment plus no recurrence occurred in 37% of patients treated with imiquimod 5% cream and 4% of those treated with placebo.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Aminoquinolines / therapeutic use. Condylomata Acuminata / drug therapy. Interferon Inducers / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Humans. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • HIV InSite. treatment guidelines - Women and HIV .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 1998 Apr;42(4):789-94 [9559784.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):25-30 [9449906.001]
  • [Cites] J Dermatol. 1998 Jul;25(7):429-33 [9714974.001]
  • [Cites] Lancet. 1998 Aug 22;352(9128):609-13 [9746022.001]
  • [Cites] Pain. 1998 Dec;78(3):209-16 [9870574.001]
  • [Cites] MMWR Recomm Rep. 1998 Jan 23;47(RR-1):1-111 [9461053.001]
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9 [9486679.001]
  • [Cites] J Clin Epidemiol. 2000 May;53(5):477-84 [10812319.001]
  • [Cites] Lancet. 1999 Nov 27;354(9193):1896-900 [10584742.001]
  • [Cites] AIDS. 1999 Dec 3;13(17):2397-404 [10597781.001]
  • [Cites] Sex Transm Infect. 1999 Aug;75 Suppl 1:S71-5 [10616389.001]
  • [Cites] Commun Dis Rep CDR Suppl. 1999 Dec;9(6):S1-12 [10635605.001]
  • [Cites] J Pain Symptom Manage. 1999 Dec;18(6):427-37 [10641469.001]
  • [Cites] Pain. 2000 Apr;85(3):415-24 [10781914.001]
  • [Cites] J Clin Epidemiol. 2000 Nov;53(11):1119-29 [11106885.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • [Cites] J Infect Dis. 1998 Aug;178(2):551-5 [9697742.001]
  • [Cites] Int J STD AIDS. 2001 Jan;12(1):22-8 [11177478.001]
  • [Cites] JAMA. 2001 Jan 24-31;285(4):437-43 [11242428.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Mar 15;292(6522):746-50 [3082422.001]
  • [Cites] BMJ. 1995 Feb 18;310(6977):452-4 [7873954.001]
  • [Cites] Arch Intern Med. 1996 Mar 25;156(6):661-6 [8629879.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Ann Intern Med. 1997 May 1;126(9):712-20 [9139558.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):635-40 [9310564.001]
  • [CommentIn] Arch Dermatol. 2002 Dec;138(12):1599-601 [12472350.001]
  • (PMID = 11401728.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC32301
  •  go-up   go-down


5. Dommergues C, Quinet B: [Treatment of pediatric genital condyloma]. Arch Pediatr; 2008 Apr;15(4):469-72
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pediatric genital condyloma].
  • [Transliterated title] Traitement des verrues génitales de l'enfant en pratique clinique.
  • Conventional wart therapies destroy infected keratinocytes rather than directly inhibiting viral infection or replication.
  • No available drug therapy effectively eliminates HPV.
  • Treatments are often disappointing for the patient, the family and the physician due to the duration of the disease and the frequency of recurrences in spite of treatment.
  • [MeSH-major] Condylomata Acuminata / drug therapy. Papillomavirus Infections / drug therapy
  • [MeSH-minor] Adult. Aminoquinolines / therapeutic use. Antiviral Agents / therapeutic use. Child. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Humans. Interferon Inducers / therapeutic use. Keratinocytes / virology. Organophosphonates / therapeutic use. Papillomaviridae

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342497.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antiviral Agents; 0 / Interferon Inducers; 0 / Organophosphonates; 8J337D1HZY / Cytosine; 99011-02-6 / imiquimod; JIL713Q00N / cidofovir
  •  go-up   go-down


6. Quave CL, Pieroni A, Bennett BC: Dermatological remedies in the traditional pharmacopoeia of Vulture-Alto Bradano, inland southern Italy. J Ethnobiol Ethnomed; 2008 Feb 06;4:5
FIU Digital Commons. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The identification of folk remedies for the skin is important both for the preservation of traditional medical knowledge and in the search for novel antimicrobial agents in the treatment of skin and soft tissue infection (SSTI).
  • Our goal is to document traditional remedies from botanical, animal, mineral and industrial sources for the topical treatment of skin ailments.
  • Remedies are used to treat laceration, burn wound, wart, inflammation, rash, dental abscess, furuncle, dermatitis, and other conditions.
  • Remedies are used to treat more than 45 skin and soft tissue conditions of both humans and animals.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ethnopharmacol. 2004 Apr;91(2-3):331-44 [15120458.001]
  • [Cites] J Ethnopharmacol. 2004 Dec;95(2-3):373-84 [15507363.001]
  • [Cites] J Ethnopharmacol. 1982 Sep;6(2):243-50 [7132403.001]
  • [Cites] Vestn Dermatol Venerol. 1990;(8):54-6 [2256382.001]
  • [Cites] J Ethnopharmacol. 1993 May;39(1):39-51 [8331961.001]
  • [Cites] J Ethnopharmacol. 1999 Jun;65(3):225-30 [10404420.001]
  • [Cites] J Ethnopharmacol. 2005 Jan 15;96(3):429-44 [15619562.001]
  • [Cites] J Ethnopharmacol. 2005 Feb 10;97(1):129-43 [15652287.001]
  • [Cites] Fitoterapia. 2005 Jan;76(1):1-25 [15664457.001]
  • [Cites] Phytochemistry. 2005 Jun;66(12):1472-5 [15921710.001]
  • [Cites] Emerg Infect Dis. 2005 Jun;11(6):868-72 [15963281.001]
  • [Cites] J Ethnopharmacol. 2005 Jul 14;99(3):367-78 [15878246.001]
  • [Cites] J Ethnopharmacol. 2005 Oct 3;101(1-3):258-70 [15978757.001]
  • [Cites] J Ethnobiol Ethnomed. 2005;1:5 [16270931.001]
  • [Cites] J Ethnobiol Ethnomed. 2005;1:2 [16270919.001]
  • [Cites] J Ethnobiol Ethnomed. 2006;2:16 [16563158.001]
  • [Cites] J Ethnopharmacol. 2006 Sep 19;107(2):259-76 [16621379.001]
  • [Cites] Phytochemistry. 2006 Dec;67(23):2568-72 [17092525.001]
  • [Cites] J Ethnobiol Ethnomed. 2006;2:52 [17156472.001]
  • [Cites] J Wound Care. 2007 Jul;16(7):298-302 [17708380.001]
  • [Cites] JAMA. 2007 Oct 17;298(15):1763-71 [17940231.001]
  • [Cites] J Ethnopharmacol. 1999 Dec 15;68(1-3):183-92 [10624877.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):829-30 [11022933.001]
  • [Cites] Fitoterapia. 2000 Aug;71 Suppl 1:S83-8 [10930717.001]
  • [Cites] J Ethnopharmacol. 2001 Dec;78(2-3):171-91 [11694363.001]
  • [Cites] Fitoterapia. 2002 Jun;73(3):217-41 [12048017.001]
  • [Cites] J Ethnopharmacol. 2002 Jul;81(2):165-85 [12065148.001]
  • [Cites] Fitoterapia. 2002 Jul;73(4):300-4 [12234572.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Dec;44(4):331-6 [12543537.001]
  • [Cites] J Ethnopharmacol. 2003 Mar;85(1):107-18 [12576209.001]
  • [Cites] J Ethnopharmacol. 2003 Dec;89(2-3):221-44 [14611886.001]
  • [Cites] Vet Res Commun. 2004 Jan;28(1):55-80 [14989363.001]
  • (PMID = 18254949.001).
  • [ISSN] 1746-4269
  • [Journal-full-title] Journal of ethnobiology and ethnomedicine
  • [ISO-abbreviation] J Ethnobiol Ethnomed
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / F31 AT004288-01A1; United States / NCCIH NIH HHS / AT / F31 AT004288; United States / NCCIH NIH HHS / AT / F31AT004288-01A1; United States / NCCIH NIH HHS / AT / T32 AT001060; United States / NCCIH NIH HHS / AT / 1T32AT01060-01; United States / NCCIH NIH HHS / AT / AT004288-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2275234
  •  go-up   go-down


7. Moore RA, Walcott S, White KL, Anderson DM, Jain S, Lloyd A, Topley P, Thomsen L, Gough GW, Stanley MA: Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology; 2003 Sep 30;314(2):630-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic immunisation with COPV early genes by epithelial DNA delivery.
  • Following challenge with COPV (canine oral papillomavirus), DNA plasmids encoding COPV L1, E1 or E2 protein were delivered into oral mucosal and cutaneous sites in beagles using particle-mediated immunotherapeutic delivery (PMID).
  • All of the control animals developed warts at the vast majority of sites (94%).
  • All of the animals given wild type L1, E1, or E2 developed warts at most sites (88%, 75%, and 88%, respectively).
  • The animals given codon optimised E2 however, were protected from wart growth with only one tiny lesion seen on a single animal that persisted for only a few days.
  • These data suggest that therapeutic immunisation by PMID with papillomavirus early genes is effective and emphasizes the importance of antigen load in the generation of protective responses to papillomavirus proteins.
  • [MeSH-major] Epithelium / virology. Papilloma / drug therapy. Papillomaviridae / immunology. Vaccines, DNA / therapeutic use. Viral Proteins / immunology. Viral Vaccines / therapeutic use
  • [MeSH-minor] Animals. Capsid Proteins / administration & dosage. Capsid Proteins / genetics. Capsid Proteins / immunology. Cell Line. Disease Models, Animal. Dogs. Humans. Immunization. Mouth Mucosa / virology. Papillomavirus Infections / drug therapy. Papillomavirus Infections / virology. Plasmids

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14554090.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / L1 protein, canine oral papillomavirus; 0 / Vaccines, DNA; 0 / Viral Proteins; 0 / Viral Vaccines
  •  go-up   go-down


8. Biete A, Valduvieco I, Rovirosa A, Farrús B, Casas F, Conill C: Whole abdominal radiotherapy in ovarian cancer. Rep Pract Oncol Radiother; 2010;15(2):27-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of the study was to evaluate the clinical outcome and toxicity after adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.
  • MATERIAL AND METHODS: Ten patients with optimal cytoreduced ovarian cancer, with a mean age of 58 years (40-70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and adjuvant chemotherapy (9/10).
  • The total radiation dose was 22.5 Gy in the whole abdomen and 42-45 Gy in the pelvis.
  • Gastrointestinal toxicity was as follows: acute 3/10 grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small bowel obstruction (SBO) that required surgery.
  • CONCLUSIONS: Whole abdominal radiotherapy after surgery and platinum-based chemotherapy achieves high locoregional disease control with an acceptable risk of acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24376920.001).
  • [ISSN] 1507-1367
  • [Journal-full-title] Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology
  • [ISO-abbreviation] Rep Pract Oncol Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3863228
  • [Keywords] NOTNLM ; Gastrointestinal toxicity / Ovarian cancer / Whole abdominal radiotherapy
  •  go-up   go-down


9. Engelen MJ, Snel BJ, Schaapveld M, Pras E, de Vries EG, Gietema JA, van der Zee AG, Willemse PH: Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer. Eur J Cancer; 2009 May;45(7):1193-200
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer.
  • The aim of the study was to evaluate long-term toxicity of adjuvant treatment in early stage ovarian cancer survivors.
  • In 93 FIGO stages I and II patients, cytoreductive and staging surgery was performed; 15 received no adjuvant treatment (controls), 39 whole abdominal radiotherapy (WART) and 39 platin-based chemotherapy.
  • In both the radiotherapy and the chemotherapy group, 50% of patients reported long-term side-effects (all grades) versus 13% of controls.
  • Two patients in the WART group died from bowel complications.
  • Of all patients alive at the last follow-up, 12/17 (71%) patients treated with radiotherapy and 11/18 (61%) treated with chemotherapy experienced long-term morbidity versus 2/9 (22%) controls (P=0.03).
  • Cisplatin-based chemotherapy caused peripheral neuropathy versus virtual absence of problems in the survivors of just surgery, emphasising the need for strict criteria before instigating adjuvant treatment.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Case-Control Studies. Chemotherapy, Adjuvant / adverse effects. Chemotherapy, Adjuvant / mortality. Cisplatin / adverse effects. Female. Follow-Up Studies. Gastrointestinal Diseases / complications. Gastrointestinal Diseases / mortality. Heart Diseases / complications. Heart Diseases / mortality. Humans. Kaplan-Meier Estimate. Middle Aged. Morbidity. Neoplasm Staging. Neoplasms, Second Primary / mortality. Peripheral Nervous System Diseases / complications. Peripheral Nervous System Diseases / mortality. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / mortality. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201598.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Baser NT, Yalaz B, Yilmaz AC, Tuncali D, Aslan G: An unusual and serious complication of topical wart treatment with monochloroacetic acid. Int J Dermatol; 2008 Dec;47(12):1295-7
Hazardous Substances Data Bank. CHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual and serious complication of topical wart treatment with monochloroacetic acid.
  • Numerous chemical agents are used in the topical treatment of warts.
  • MCAA is a strong organic acid which is irritating and corrosive to the skin and has a high systemic toxicity.
  • In addition to wart treatment, it is used for industrial purposes, such as the synthesis of certain organic chemicals.
  • We present a case of joint deformity manifesting after the use of a preparation containing MCAA for topical wart treatment.
  • This underlines the need to reassess the safety of MCAA use for topical wart treatment.
  • [MeSH-major] Acetates / adverse effects. Finger Injuries / chemically induced. Hand Deformities, Acquired / chemically induced. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Finger Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126020.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 5GD84Y125G / chloroacetic acid
  •  go-up   go-down


11. Sardana K, Garg V, Relhan V: Complete resolution of recalcitrant periungual/subungual wart with recovery of normal nail following "prick" method of administration of bleomycin 1%. Dermatol Ther; 2010 Jul-Aug;23(4):407-10
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resolution of recalcitrant periungual/subungual wart with recovery of normal nail following "prick" method of administration of bleomycin 1%.
  • We report a case of 14 year old girl with recalcitrant subungual wart which responded dramatically to bleomycin with normal nail regrowth.
  • [MeSH-major] Bleomycin / therapeutic use. Nail Diseases / drug therapy. Warts / drug therapy
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666828.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


12. Chong WS, Kang GY: Dramatic clearance of a recalcitrant acral viral wart using methyl aminolevulinate-red light photodynamic therapy. Photodermatol Photoimmunol Photomed; 2009 Aug;25(4):225-6
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic clearance of a recalcitrant acral viral wart using methyl aminolevulinate-red light photodynamic therapy.
  • A 20-year-old man presented with a 3-month history of a viral wart located on his right thumb.
  • Cryotherapy was administered weekly to the wart over 5 months without any significant improvement.
  • A decision was made to treat the wart with red light photodynamic therapy (PDT) using topical methyl aminolevulinate (MAL) administered as three treatments 1-week apart.
  • The patient was reviewed 4 weeks after the third treatment and the wart was found to have cleared completely.
  • Three months after the last treatment, there remained no clinical evidence of recurrence of the wart.
  • Pain was the main problem with the treatment but it was tolerable.
  • Although the successful treatment of recalcitrant acral viral warts with PDT using 5-aminolevulinic acid (ALA) is well documented, this is the first report of the successful PDT treatment of a recalcitrant acral viral wart using the methylester derivative of ALA.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Light. Photochemotherapy. Photosensitizing Agents / administration & dosage. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614904.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


13. Tucker SB, Ali A, Ransdell BL: Plantar wart treatment with combination imiquimod and salicylic acid pads. J Drugs Dermatol; 2003 Jan;2(1):70-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plantar wart treatment with combination imiquimod and salicylic acid pads.
  • Treatment of plantar warts is often difficult and may be painful, often employing destructive treatment modalities.
  • We report the successful treatment of a patient with a large plantar wart using Imiquimod 5% cream under occlusion with a 40% salicylic acid pad.
  • This combination treatment modality likely allows successful delivery of Imiquimod through the thick skin on the plantar surface.
  • Once penetrated, an anti-viral state is created by upregulating specific cytokines to eradicate the human papilloma virus (HPV).
  • [MeSH-major] Aminoquinolines / administration & dosage. Foot / pathology. Salicylic Acid / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Drug Therapy, Combination. Humans. Male

  • MedlinePlus Health Information. consumer health - Foot Health.
  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. SALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] J Drugs Dermatol. 2003 Apr;2(2):124-6 [12905977.001]
  • (PMID = 12852385.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down


14. Leitner J, Hofbauer F, Ackerl M: [Poisoning with a podophyllin-containing wart-treating tincture]. Dtsch Med Wochenschr; 2002 Jul 12;127(28-29):1516-20
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Poisoning with a podophyllin-containing wart-treating tincture].
  • [Transliterated title] Vergiftung mit Podophyllin-haltiger Warzentinktur.
  • DIAGNOSIS, TREATMENT AND COURSE: The patient became comatose within 5 hours, acidotic, oliguric, required ventilation and went into severe shock.
  • The symptoms and the fact that podophyllin (pod.) was the main agent in the wart preparation confirmed the suspicion of pod. poisoning.
  • While the potential toxicity of the resin, taken either orally or applied externally, has been long known, the poorly definied raw product is still being added to anti-wart tinctures.
  • [MeSH-minor] Administration, Oral. Alcoholism. Coma / chemically induced. Depression / chemically induced. Esophagus / injuries. Esophagus / pathology. Hospitalization. Humans. Male. Middle Aged. Platelet Count. Podophyllin / chemistry. Podophyllin / poisoning. Podophyllin / therapeutic use. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111657.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratolytic Agents; 9000-55-9 / Podophyllin; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


15. Tucker SB, Ali A, Ransdell BL: Plantar wart treatment with combination imiquimod and salicylic acid pads. J Drugs Dermatol; 2003 Apr;2(2):124-6
Hazardous Substances Data Bank. SALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plantar wart treatment with combination imiquimod and salicylic acid pads.
  • Treatment of plantar warts is often difficult and may be painful, often employing destructive treatment modalities.
  • We report the successful treatment of a patient with a large plantar wart using Imiquimod 5% cream under occlusion with a 40% salicylic acid pad.
  • This combination treatment modality likely allows successful delivery of Imiquimod through the thick skin on the plantar surface.
  • Once penetrated, an anti-viral state is created by upregulating specific cytokines to eradicate the human papilloma virus (HPV).
  • [MeSH-major] Aminoquinolines / administration & dosage. Foot / pathology. Salicylic Acid / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Drug Therapy, Combination. Humans. Male

  • MedlinePlus Health Information. consumer health - Foot Health.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] J Drugs Dermatol. 2003 Jan;2(1):70-2 [12852385.001]
  • (PMID = 12905977.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Corrected and Republished Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down


16. Lin MY, Xiang LH: Topical 5-aminolevulinic acid photodynamic therapy for recalcitrant facial flat wart in Chinese subjects. J Dermatol; 2008 Oct;35(10):658-61
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-aminolevulinic acid photodynamic therapy for recalcitrant facial flat wart in Chinese subjects.
  • The facial flat wart (verruca plana) is not only a contagious viral disease, but also causes a disturbing cosmetic problem.
  • Because 5-aminolevulinic acid photodynamic therapy has successfully treated human papilloma virus-related diseases, we employed 20% 5-aminolevulinic acid and a light emitting diode on three recalcitrant facial flat wart patients.
  • An ablative therapeutic mode is required in addition to 5-aminolevulinic acid photodynamic therapy in such lesions.
  • Therefore, we utilized an Er:YAG laser and 20% 5-aminolevulinic acid photodynamic therapy for one session and achieved an excellent result.
  • Patients should be informed of the possible side-effects of this treatment, such as erythema, exfoliation and post-inflammatory hyperpigmentation, and the requirement for sun protection.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Facial Dermatoses / drug therapy. Photochemotherapy. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017045.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


17. O'Mahony C: Difficult wart cases -- use of imiquimod cream 5%. Int J STD AIDS; 2001 Jun;12(6):400-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficult wart cases -- use of imiquimod cream 5%.
  • Treatment of genital warts is a significant part of genitourinary medicine work load.
  • Home therapies are the sensible way forward.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Condylomata Acuminata / drug therapy. Penile Diseases / drug therapy
  • [MeSH-minor] Adolescent. Adult. Anus Diseases / drug therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Penis Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11368824.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; P1QW714R7M / imiquimod
  •  go-up   go-down


18. Meltzer SM, Monk BJ, Tewari KS: Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol; 2009 Mar;200(3):233.e1-7
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green tea catechins for treatment of external genital warts.
  • Two randomized trials evaluating the activity and efficacy of green tea catechins in the management of external genital warts are presented, and the reported side effects associated with this topical treatment modality are outlined.
  • Finally, the mechanism of action, percent of wart clearance, time to clearance, and toxicity profile of green tea catechins are compared with those of podofilox and imiquimod, 2 other patient-administered topical agents approved for treatment of anogenital warts.
  • [MeSH-major] Catechin / therapeutic use. Condylomata Acuminata / drug therapy. Phytotherapy. Plant Extracts / therapeutic use. Tea
  • [MeSH-minor] Animals. Antiviral Agents / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019336.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Plant Extracts; 0 / Tea; 8R1V1STN48 / Catechin
  • [Number-of-references] 24
  •  go-up   go-down


19. Serarslan G, Balci DD, Homan S: Acitretin treatment in acrokeratosis verruciformis of Hopf. J Dermatolog Treat; 2007;18(2):123-5
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acitretin treatment in acrokeratosis verruciformis of Hopf.
  • Acrokeratosis verruciformis of Hopf is a rare disorder and characterized by flesh-coloured, wart-like, flat papules on the dorsum of the hands and feet.
  • The disease is an autosomal disorder, but sporadic cases also occur.
  • [MeSH-major] Acitretin / therapeutic use. Keratolytic Agents / therapeutic use. Keratosis / diagnosis. Keratosis / drug therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Foot Dermatoses / diagnosis. Foot Dermatoses / drug therapy. Foot Dermatoses / pathology. Hand Dermatoses / diagnosis. Hand Dermatoses / drug therapy. Hand Dermatoses / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520472.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratolytic Agents; LCH760E9T7 / Acitretin
  •  go-up   go-down


20. Sidbury R: What's new in pediatric dermatology: update for the pediatrician. Curr Opin Pediatr; 2004 Aug;16(4):410-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Common pediatric skin conditions such as infantile atopic dermatitis, vitiligo, hemangiomas of infancy, warts, and molluscum contagiosum do not always respond to standard therapy.
  • In some settings pediatricians will use "off-label" medications if the benefit-to-risk ratio is favorable.
  • This article reviews important literature from the past year related to "off-label" immune-based treatment of skin disease, using the topical immunomodulators tacrolimus, pimecrolimus, and imiquimod, as well as intravenous Ig.
  • Imiquimod, another topical immunomodulator, approved for genital wart treatment in adults, has also been examined for "off-label" pediatric use in nongenital warts, molluscum contagiosum, hemangiomas of infancy, and basal cell carcinoma.
  • SUMMARY: In the absence of larger controlled trials, pediatricians must consider the cumulative weight of smaller studies with their personal experience when assessing any role for "off label" therapy.
  • [MeSH-major] Skin / drug effects. Skin Diseases / drug therapy. Tacrolimus / analogs & derivatives
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Child. Clinical Trials as Topic. Dermatitis, Atopic / drug therapy. Hemangioma / drug therapy. Humans. Immunoglobulins / therapeutic use. Immunologic Factors / therapeutic use. Immunosuppressive Agents / therapeutic use. Infant. Molluscum Contagiosum / drug therapy. Stevens-Johnson Syndrome / drug therapy. Vitiligo / drug therapy. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15273502.001).
  • [ISSN] 1040-8703
  • [Journal-full-title] Current opinion in pediatrics
  • [ISO-abbreviation] Curr. Opin. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Immunoglobulins; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 7KYV510875 / pimecrolimus; 99011-02-6 / imiquimod; WM0HAQ4WNM / Tacrolimus
  • [Number-of-references] 37
  •  go-up   go-down


21. Dé Tran QH, Guay E, Chartier S, Tousignant J: Tacrolimus in dermatology. J Cutan Med Surg; 2001 Jul-Aug;5(4):329-35
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tacrolimus (FK 506), a metabolite of the fungus Streptomyces tsukubaensis, is an anti-T-cell drug.
  • Short-term trials of topical tacrolimus in the treatment of atopic dermatitis have recently shown excellent results in both adults and children.
  • In animal studies of hair growth disorders, topical tacrolimus induces anagen and protects from chemotherapy-induced alopecia.
  • Animal studies with the ointment for the prevention of skin graft rejection, lupus dermatoses, and skin papilloma formation have also shown to be promising.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Skin Diseases / drug therapy. Tacrolimus / therapeutic use
  • [MeSH-minor] Administration, Oral. Administration, Topical. Adult. Animals. Behcet Syndrome / drug therapy. Child. Clinical Trials as Topic. Cricetinae. Dermatitis, Atopic / drug therapy. Dermatitis, Contact / drug therapy. Double-Blind Method. Hair / drug effects. Hair / growth & development. Humans. Lupus Erythematosus, Cutaneous / drug therapy. Mice. Placebos. Psoriasis / drug therapy. Pyoderma Gangrenosum / drug therapy. Randomized Controlled Trials as Topic. Rats. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy. Skin Transplantation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11907845.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Placebos; WM0HAQ4WNM / Tacrolimus
  • [Number-of-references] 38
  •  go-up   go-down


22. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, Noël JC, Wulfsohn MS, Rooney JF, Jaffe HS, De Clercq E: Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis; 2001 Sep 1;33(5):597-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.
  • Genital condylomata acuminata are nonmalignant human papillomavirus (HPV)-induced tumors in which HPV types 6 and 11 are most commonly found.
  • Usual treatments for condylomata acuminata are nonspecific and are based on the destruction or removal of infected tissue.
  • We report here what is to our knowledge the first double-blind, placebo-controlled study of the use of cidofovir, a nucleotide analogue, for the treatment of genital papillomavirus infections.
  • The median number of warts and the median baseline wart area were comparable for both groups.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / therapeutic use. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papillomaviridae / drug effects. Papillomavirus Infections / drug therapy. Tumor Virus Infections / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Risk Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11477525.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


23. Saiag P, Bauhofer A, Bouscarat F, Aquilina C, Ortonne JP, Dupin N, Mougin C: Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol; 2009 Oct;161(4):904-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.
  • High-risk (HR) human papillomaviruses (HPVs), especially types 16 and 18, are major risk factors for precancerous and cancerous lesions of the anogenital tract, while low-risk (LR) HPVs are associated with benign lesions.
  • Treatment with imiquimod cream showed a total clearance of external genital or perianal warts in about 50% of immunocompetent subjects.
  • However, total clearance was reduced in HIV+ subjects not treated with highly active antiretroviral therapy (HAART).
  • Imiquimod 5% cream was applied on external genital or perianal warts three times weekly for up to 16 weeks.
  • Warts were tested at entry and after treatment for human LR- and HR-HPV DNA.
  • RESULTS: Total wart clearance was observed in 16 of 50 (32%) patients at week 16.
  • CONCLUSIONS: Imiquimod 5% cream did not show safety concerns and is suitable for use in HIV+ subjects with anogenital warts and successful HAART treatment.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Anus Diseases / drug therapy. Condylomata Acuminata / drug therapy. Papillomavirus Infections / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Adolescent. Adult. Antiretroviral Therapy, Highly Active. Drug Administration Schedule. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466962.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00761371
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


24. Jacobs S, Grussendorf-Conen EI, Rösener I, Rübben A: Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts. Skin Pharmacol Physiol; 2004 Sep-Oct;17(5):258-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts.
  • Imiquimod is effective in the treatment of genital warts and clinical studies suggest activity against common warts as well.
  • We have analyzed the effect of topical imiquimod on gene expression and virus load in human papilloma virus (HPV) 2/27/57-induced common warts. mRNA was extracted from keratinocyte culture, from normal skin, from three untreated common warts and from three common warts treated topically with 5% imiquimod cream twice daily.
  • We further analyzed viral DNA content in scales from three superficially pared imiquimod-treated warts by real-time PCR.
  • Comparison of normal skin with wart tissue revealed that HPV 2/27/57 infection led to an induction of IL-6, IL-10 and interferon-gamma inducible protein (IP10) and to an up-regulation of TGF-beta.
  • We could further detect expression of PCTAIRE-3, WNT2B, frizzled-3, notch-2, notch-4 and BRCA2 in normal skin and common warts.
  • It could also be shown that imiquimod led to an infiltration of wart tissue with macrophages and to a strong decrease of viral copy number in warts within 3 months of treatment.
  • Our data thus provide molecular proof of principle for imiquimod treatment of cutaneous common warts.
  • [MeSH-major] Aminoquinolines / administration & dosage. Oligonucleotide Array Sequence Analysis / methods. Papillomaviridae / drug effects. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel
  • (PMID = 15452412.001).
  • [ISSN] 1660-5527
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / DNA, Viral; 0 / Interleukins; 0 / RNA, Messenger; 99011-02-6 / imiquimod
  •  go-up   go-down


25. Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B: Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):208-16
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
  • The majority of patients with clinical Stage I UPSC are found to have extrauterine disease at the time of surgery.
  • Surgical treatment as the sole therapy for patients with Stage I-IV UPSC is unacceptable because of high recurrence rates.
  • Chemotherapy, radiotherapy, or both have been added after surgery in an attempt to improve survival.
  • However, the survival benefit to patients from such multimodality therapy remains uncertain.
  • This study analyzes the patterns of failure in patients with FIGO Stages I-IV UPSC treated by multimodality therapy.
  • METHODS AND MATERIALS: Forty-two women with FIGO Stages I-IV UPSC who were treated by multimodality therapy were analyzed retrospectively between 1988 and 1998.
  • Data were obtained from tumor registry, hospital, and radiotherapy chart reviews, operative notes, pathology, and chemotherapy flow sheets.
  • All the patients underwent staging laparotomy, peritoneal cytology, total abdominal hysterectomy and salpingo oophorectomy, pelvic and para-aortic lymph node sampling, omentectomy, and cytoreductive surgery, when indicated followed by radiotherapy and/or chemotherapy.
  • Therapy consisted of external beam radiation therapy in 11 patients (26%), systemic chemotherapy in 20 (48%), and both radiotherapy and chemotherapy in 11 (26%).
  • The treatments were not assigned in a randomized fashion.
  • The dose of external beam radiation therapy ranged from 45-50.40 Gy (median 45).
  • Of the 31 patients (74%) who received chemotherapy, 18 received single-agent (58%), whereas 13 received multiagent chemotherapy (42%).
  • Twenty-nine patients (69%) had suffered recurrence at the time of last follow-up.
  • Twenty-five patients (60%) had died at the time of reporting; the observed survival rate at 2 years and 5 years was 52% and 43%, respectively.
  • CONCLUSIONS: Our data suggest that, after multimodality therapy of FIGO Stage I-IV UPSC, most patients developed abdominopelvic (locoregional) failure, and the great majority of the failures occurred in the abdomen, vagina, and pelvis (66%).
  • Distant failure alone occurred in 17% of the patients.We propose that future studies should combine whole abdominal radiotherapy (WART) with pelvic and vaginal boosts, in addition to chemotherapy for FIGO Stage I-IV UPSC, especially in patients with minimal residual disease, to attempt to improve the dismal prognosis of patients with UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Neoplasm Recurrence, Local / diagnosis. Uterine Neoplasms / mortality. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging / methods. Paclitaxel / administration & dosage. Retrospective Studies. Shiga Toxins / administration & dosage. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909235.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Shiga Toxins; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Iraji F, Kiani A, Shahidi S, Vahabi R: Histopathology of skin lesions with warty appearance in renal allograft recipients. Am J Dermatopathol; 2002 Aug;24(4):324-5
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology of skin lesions with warty appearance in renal allograft recipients.
  • These patients also demonstrate an accelerated course from wart to carcinoma.
  • Median time from transplantation was 49 months (<5 years).
  • [MeSH-major] Kidney Transplantation / adverse effects. Skin Diseases / pathology. Warts / pathology
  • [MeSH-minor] Biopsy. Drug Therapy, Combination. Humans. Immunocompromised Host. Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12142612.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


27. O'Mahony C, Law C, Gollnick HP, Marini M: New patient-applied therapy for anogenital warts is rated favourably by patients. Int J STD AIDS; 2001 Sep;12(9):565-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New patient-applied therapy for anogenital warts is rated favourably by patients.
  • Our objective was to determine patient attitudes to having genital warts, and their perceptions of their treatment with imiquimod and other therapies.
  • The majority of patients (70%) had been previously treated for genital warts, and expressed dissatisfaction with their previous therapies.
  • Sixty-one per cent of patients perceived that their warts completely cleared within the 16-week treatment period.
  • Patients rated imiquimod 5% cream as better than other genital wart therapies in terms of overall satisfaction, time to clearance, convenience and lack of associated pain.
  • In conclusion, patients rated imiquimod 5% cream as an effective treatment which clears warts in an acceptable length of time causing minimal pain and is convenient to use.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Male / drug therapy. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Female. Follow-Up Studies. Health Knowledge, Attitudes, Practice. Humans. Male. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11516364.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  •  go-up   go-down


28. Chen HM: [Verruca planae Chinese medicine treatment]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Aug;22(4):302-4
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verruca planae Chinese medicine treatment].
  • OBJECTIVE: Flat wart on the effectiveness of TCM treatment.
  • Treatment and control groups.
  • Treatment groups treated with Chinese herbs.
  • 5 g pre pack, after treatment for 30 days, clinical observation.
  • CONCLUSION: Chinese medicine has some effect flat wart.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Medicine, Chinese Traditional. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105351.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


29. Herrera S, Correa LA, Wolff JC, Gaviria A, Tyring SK, Sanclemente G: Effect of imiquimod in anogenital warts from HIV-positive men. J Clin Virol; 2007 Jul;39(3):210-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 43 patients enrolled, 86% completed treatment.
  • Thirty-one patients were receiving highly active antiretroviral therapy (HAART) therapy.
  • At week 16, 10 patients completely cleared lesions and 21 patients had a wart size reduction > or =50%.
  • At 20 weeks of therapy, 17 patients achieved total clearance whereas 14 patients had a >50% wart reduction.
  • Clearance was not influenced by CD4-counts, HIV-viral load, previous therapy, or wart localization.
  • Mean time of recurrence was 14.4 weeks.
  • Erythema, pruritus, and burning sensation were the most frequent local skin reactions.
  • It is also useful to decrease wart recurrence.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Anus Diseases / drug therapy. Condylomata Acuminata / drug therapy. Genital Diseases, Male / drug therapy. HIV Infections / complications. Interferon Inducers / therapeutic use
  • [MeSH-minor] AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / virology. Administration, Topical. Adult. Antiretroviral Therapy, Highly Active. Humans. Male. Middle Aged. Secondary Prevention. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513167.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


30. Mitsuhashi Y, Kawaguchi M, Hozumi Y, Kondo S: Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol; 2005 Jun;32(6):420-3
Hazardous Substances Data Bank. CHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Senile wart or seborrheic keratosis is a benign tumor which occurs mainly in the elderly.
  • It has traditionally been treated with surgical procedures, freezing with liquid nitrogen, or laser therapy.
  • Out of 116 cases treated for 3 to 12 months, 35 (30.2%) showed complete disappearance or more than an 80% decrease in the volume of the tumor, 54 cases (46.6%) showed a decrease in the volume between 40 and 80%, and no remarkable changes or decreases of less than 40% were seen in 27 cases (23.3%).
  • An organ culture experiment using senile wart as a material with several concentrations of tacalcitol revealed that tacalcitol induced apoptosis in the tissue.
  • [MeSH-major] Cholecalciferol / therapeutic use. Keratosis, Seborrheic / drug therapy. Keratosis, Seborrheic / pathology
  • [MeSH-minor] Administration, Topical. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Prospective Studies. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043912.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1C6V77QF41 / Cholecalciferol
  •  go-up   go-down


31. Dowdy SC, Constantinou CL, Hartmann LC, Keeney GL, Suman VJ, Hillman DW, Podratz KC: Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. Gynecol Oncol; 2003 Dec;91(3):563-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Previous reports indicate that cytoreduction and salvage therapy with P32 or whole abdominal radiation may improve survival in patients with positive findings at second-look laparotomy (SLL).
  • METHODS: From 1977 (the year platinum-based chemotherapy was introduced to our institution) to 1989, 150 patients had persistent disease at SLL.
  • Median actuarial survival from the time of SLL was 18 months.
  • Tumor grade (P = 0.003) and pre- and post-SLL tumor size (P < 0.0001) were significant determinants of survival by univariate analysis.
  • After adjusting for tumor size, salvage treatment was not a significant predictor of survival.
  • CONCLUSION: With long-term follow-up there was no suggestion that the type of salvage therapy (e.g., P32 or WART) influenced survival.
  • Rather, low-grade disease and low tumor burdens following cytoreduction were associated with improved survival on multivariate analysis.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Laparotomy. Middle Aged. Organoplatinum Compounds / therapeutic use. Retrospective Studies. Salvage Therapy. Second-Look Surgery. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675677.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


32. Dasher DA, Burkhart CN, Morrell DS: Immunotherapy for childhood warts. Pediatr Ann; 2009 Jul;38(7):373-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment-resistant warts are a common and frustrating problem for patients, parents, and providers alike.
  • No wart treatment is uniformly effective.
  • Indeed, well-designed randomized controlled trials are sorely needed to establish the true efficacy of all wart therapies.
  • Treatment should be tailored to each individual patient.
  • Although none of the immunologically-based treatments listed above (see Table, page 377) is FDA-approved for warts, they provide the treating physician with options for patients with warts that are resistant to standard treatments.
  • [MeSH-major] Immunotherapy / methods. Warts / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antigens / therapeutic use. Child. Child, Preschool. Cimetidine / therapeutic use. Cyclobutanes / therapeutic use. Cyclopropanes / therapeutic use. Dinitrochlorobenzene / therapeutic use. Histamine H2 Antagonists / therapeutic use. Humans. Injections, Intralesional. Irritants / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19685657.001).
  • [ISSN] 0090-4481
  • [Journal-full-title] Pediatric annals
  • [ISO-abbreviation] Pediatr Ann
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antigens; 0 / Cyclobutanes; 0 / Cyclopropanes; 0 / Histamine H2 Antagonists; 0 / Irritants; 4RTO57VG65 / squaric acid dibutyl ester; 80061L1WGD / Cimetidine; 99011-02-6 / imiquimod; GE3IBT7BMN / Dinitrochlorobenzene; I7G14NW5EC / diphenylcyclopropenone
  • [Number-of-references] 39
  •  go-up   go-down


33. Armour K, Orchard D: Treatment of palmoplantar warts with a diphencyprone and salicylic acid ointment. Australas J Dermatol; 2006 Aug;47(3):182-5
Hazardous Substances Data Bank. SALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of palmoplantar warts with a diphencyprone and salicylic acid ointment.
  • The time to wart clearance ranged from less than 4 weeks to 4 months.
  • In our patient group, 90% rated their treatment as 'excellent' or 'good', whereas 10% stated that the reaction induced by diphencyprone was 'too severe'.
  • Our results are compared with those previously published using diphencyprone in the treatment of palmoplantar warts.
  • [MeSH-major] Cyclopropanes / administration & dosage. Foot Dermatoses / drug therapy. Hand Dermatoses / drug therapy. Keratolytic Agents / administration & dosage. Salicylic Acid / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Combinations. Follow-Up Studies. Humans. Middle Aged. Patient Satisfaction. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866999.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cyclopropanes; 0 / Drug Combinations; 0 / Keratolytic Agents; I7G14NW5EC / diphenylcyclopropenone; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down


34. Zschocke I, Hartmann A, Schlöbe A, Cummerow R, Augustin M: [Efficacy and benefit of a 5-FU/salicylic acid preparation in the therapy of common and plantar warts--systematic literature review and meta-analysis]. J Dtsch Dermatol Ges; 2004 Mar;2(3):187-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and benefit of a 5-FU/salicylic acid preparation in the therapy of common and plantar warts--systematic literature review and meta-analysis].
  • [Transliterated title] Wirksamkeit und Nutzen eines 5-FU-/Salicylsäurehaltigen Präparates in der Therapie vulgärer und plantarer Warzen--systematische Literaturüibersicht und Metaanalyse.
  • BACKGROUND:. (1) Salicylic acid (SA) and 5-Fluorouracil (5-FU) are effective drugs in wart therapy. (2) In Germany, increasing data on the benefit and the economic efficiency of drugs at Level I of evidence-based medicine are needed.
  • METHODS: Evaluation of the effectiveness and benefits of a drug combination containing 0.5 % 5-FU and 10% SA in the therapy of (a) common and (b) plantar warts in form of a two-step procedure--(1) Systematic literature analysis, (2) Meta-analysis of the randomised-controlled studies (RCTs). RESULTS:.
  • (1) The efficacy of 5-FU/SA therapy was tested in a total of 625 patients (n=8 RCTs) with common warts and 101 patients (n=4 RCTs) with plantar warts.
  • The therapeutic effect across all studies in common warts was 63.4% response (complete healing) for 5-FU/SA vs. 23.1% for the 5-FU-free controls, respectively.
  • CONCLUSION: The combination of 5-FU and SA is an effective and beneficial therapy for common and plantar warts.
  • [MeSH-major] Aspirin / administration & dosage. Fluorouracil / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Risk Assessment / methods. Warts / drug therapy. Warts / epidemiology
  • [MeSH-minor] Drug Combinations. Foot. Humans. Internationality. Prognosis. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16281635.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; R16CO5Y76E / Aspirin; U3P01618RT / Fluorouracil
  • [Number-of-references] 31
  •  go-up   go-down


35. Mitsuhashi Y: [New aspects on vitamin D3 ointment; treatment of senile warts with topical application of active forms of vitamin D3]. Clin Calcium; 2004 Oct;14(10):141-4
Hazardous Substances Data Bank. CHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New aspects on vitamin D3 ointment; treatment of senile warts with topical application of active forms of vitamin D3].
  • Vitamin D(3) ointment is widely used for the therapy of inflammatory keratotic dermatoses such as psoriasis.
  • Senile wart (seborrheic keratosis) is a benign tumor, which occurs mainly in the elderly.
  • It has been treated with surgical procedures, freezing with liquid nitrogen, or laser therapy.
  • We tried to treat senile wart with active forms of topical vitamin D(3) (tacalcitol, calcipotriol or maxacalcitol).
  • Out of 116 cases those were treated for more than three months, 35 cases (30.2%) showed excellent response that means more than 80% of decreasing of tumor volume, 54 cases (46.6%) showed moderate response that means 40 to 80% of decreasing, 27 cases (23.2%) showed no remarkable changes or decreasing less than 40%.
  • The tumor disappeared without any inflammatory change such as erythema or swelling.
  • [MeSH-major] Cholecalciferol / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Humans. Ointments. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577148.001).
  • [ISSN] 0917-5857
  • [Journal-full-title] Clinical calcium
  • [ISO-abbreviation] Clin Calcium
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ointments; 1C6V77QF41 / Cholecalciferol
  •  go-up   go-down


36. Brady S, Wilson JD: Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts. J Eur Acad Dermatol Venereol; 2004 May;18(3):314-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts.
  • A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed.
  • The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment.
  • The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%.
  • Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines.
  • Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response.
  • Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts.
  • [MeSH-major] Aminoquinolines / therapeutic use. Condylomata Acuminata / drug therapy. Genital Diseases, Female / drug therapy. Genital Diseases, Male / drug therapy. Interferon Inducers / therapeutic use. Medical Audit
  • [MeSH-minor] Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Feedback. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Immunohistochemistry. Incidence. Male. Recurrence. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15096142.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


37. Firat S, Murray K, Erickson B: High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):201-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
  • PURPOSE: To evaluate the role of high-dose whole abdominal and pelvic irradiation (WART) in the treatment of epithelial ovarian carcinoma.
  • METHODS AND MATERIALS: A retrospective review was performed on 71 patients with Stage I-III ovarian carcinoma who were treated with WART using an open field technique after total abdominal hysterectomy and bilateral oophorectomy with or without omentectomy.
  • None of the patients had received chemotherapy before RT.
  • Thirty-one patients received Alkeran or cyclophosphamide and two received cisplatin-based chemotherapy after WART.
  • The median whole abdominal dose was 36 Gy (range 9-45.5), delivered in a median of 30 fractions (range 8-46).
  • The median pelvic dose was 51 Gy (range 16-59).
  • The right lobe and a portion of the left lobe of the liver were shielded with custom blocks at a median dose of 25 Gy (range 9-41).
  • The median dose to the kidneys was 19 Gy (range 4-30).
  • For this group, a total abdominal dose of > or /=36 Gy was associated with a longer overall survival independent of stage, grade, and the amount of residual disease.
  • This was most likely due to a significant reduction in the incidence of abdominal recurrence in patients receiving >36 Gy to the whole abdomen (18% vs. 49%, p = 0.006).
  • Twenty-one percent (n = 15) of the patients developed Grade 3 or 4 (Radiation Therapy Oncology Group [RTOG] criteria) chronic small or large bowel toxicity.
  • A whole abdominal dose >30 Gy and a pelvic dose >50 Gy were associated with a significant increase in small bowel obstruction (p = 0.01) independent of other factors.
  • CONCLUSION: Survival after RT for ovarian carcinoma rivals that achieved with systemic chemotherapy.
  • Careful attention to balancing toxicity and efficacy is imperative if RT is to have a future role in the treatment of this disease.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909234.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


38. Hepp R, Baeza MR, Olfos P, Suarez E: Adjuvant whole abdominal radiotherapy in epithelial cancer of the ovary. Int J Radiat Oncol Biol Phys; 2002 Jun 1;53(2):360-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Between January 1985 and April 1998, 60 patients were treated with adjuvant whole abdominal radiotherapy (A-WART).
  • Of the 60 patients, 19 also received platinum-based chemotherapy; in 12 of the 19, the chemotherapy was before A-WART.
  • A-WART consisted of 22 Gy in 22 fractions, at 5 fractions weekly in 90% of the patients.
  • The remaining 10% received 25 Gy in 25 fractions within 5 weeks.
  • The A-WART was delivered using a 4-MV linear accelerator.
  • After abdominal irradiation, a boost to the pelvis was given to reach 45 Gy at 1.8 cGy/fraction, using a 4-15-MV linear accelerator.
  • RESULTS: Treatment was delivered in a median of 50 days (range 48-70).
  • In 12 (20%) of the 60 patients, a transient treatment interruption occurred because of acute toxicity, mainly vomiting and diarrhea.
  • For patients receiving chemotherapy, the 5-year survival rate was 51%, not statistically different from the 58% 5-year survival rate observed among those patients without adjuvant chemotherapy (p = 0.9).
  • Two patients died of intestinal occlusion, both had undergone previous abdominal procedures and in 1, no tumor was found in the abdomen at the postmortem examination.
  • CONCLUSION: A-WART achieves a quite favorable 5-year survival rate with a low complication rate in properly selected patients.
  • A-WART should be included in the elective postoperative treatment of ovarian cancer patients who are at risk of abdominal failure, and this should be explored in a randomized trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023140.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR: Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum; 2002 Apr;45(4):502-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of squamous intraepithelial lesions to prevent cancer often requires extensive surgery.
  • Patients with warts by physical examination at baseline were scored at 24 weeks as to the percent reduction in wart size.
  • The reduction in size in most patients greatly diminished the procedure necessary for complete ablation.
  • This activity crosses multiple human papillomavirus types.
  • [MeSH-major] Anus Diseases / therapy. Anus Neoplasms / therapy. Bacterial Proteins. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chaperonins / pharmacology. Chaperonins / therapeutic use. Condylomata Acuminata / therapy. Immunotherapy. Oncogene Proteins, Viral / pharmacology. Oncogene Proteins, Viral / therapeutic use. Papillomaviridae / drug effects. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12006932.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Chaperonin 60; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / heat-shock protein 65, Mycobacterium; 0 / oncogene protein E7, Human papillomavirus type 16; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


40. Schroeter CA, Pleunis J, van Nispen tot Pannerden C, Reineke T, Neumann HA: Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg; 2005 Jan;31(1):71-5
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy: new treatment for therapy-resistant plantar warts.
  • BACKGROUND: Plantar wart treatment remains a challenging one.
  • Various treatment modalities have been previously used and are still in current use.
  • The problem remains in the degree of response to these treatments and the side effects associated with them.
  • OBJECTIVE: The aim of this study was to test a new treatment modality for therapy-resistant plantar warts.
  • METHODS: Thirty-one patients with 48 plantar warts were randomly selected from the Department of Laser Therapy, Medical Centre Maastricht, The Netherlands.
  • The mean incubation time was 6.8 hours, and the mean treatment time was 18.7 minutes per wart.
  • Each wart was treated an average of 2.3 times, with a median fluence of 100 cm2.
  • A trend was found between total clearance and size of the warts, age of the patient, and the mean treatment time.
  • CONCLUSION: This study showed that recalcitrant plantar warts were successfully treated with no significant side effects; however, the user needs sufficient experience for this new effective treatment application.
  • [MeSH-major] Foot Dermatoses / drug therapy. Photochemotherapy / methods. Warts / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aminolevulinic Acid / therapeutic use. Child. Humans. Logistic Models. Male. Middle Aged. Photosensitizing Agents / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720099.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


41. Wong FC, Pang CP, Tang SK, Tung SY, Leung TW, Sze WK, Cheung KB: Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement. Clin Oncol (R Coll Radiol); 2004 Aug;16(5):350-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement.
  • AIMS: To review the treatment results of patients with endometrial carcinoma having positive peritoneal washing (PPW), adnexal involvement, uterine serosal involvement, or all three.
  • MATERIALS AND METHODS: The treatment records of patients who had undergone primary surgery for endometrial cancer without distant metastasis during 1990--2001 at the Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, were reviewed.
  • Thirty-three (94.3%) patients received adjuvant radiotherapy (28 whole-pelvic irradiation [WPI]; five abdominal radiotherapy [WART]).
  • Two patients with solitary ovarian metastasis received chemotherapy, and one with isolated PPW also received adjuvant hormonal therapy.
  • RESULTS: Among the 28 patients with clinical or pathological node-negative disease (International Federation of Gynecology and Obstetrics [FIGO] stage IIIA), only two patients with solitary ovarian metastases developed recurrence.
  • Five out of the seven patients with lymph-node involvement developed recurrences.
  • Only one patient (3.7%) who had received WART developed grade 4 toxicity.
  • CONCLUSIONS: This study showed that good treatment results could be obtained from patients with stage IIIA endometrial carcinoma without clinical or pathological lymph-node involvement after adjuvant radiotherapy, with acceptable late side-effects.
  • The relative prognostic importance of individual IIIA involvement and the optimal adjuvant treatment remain to be determined.
  • [MeSH-major] Ascitic Fluid / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Myometrium / pathology. Neoplasm Staging. Ovary / pathology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Review Literature as Topic. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15341439.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1154-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
  • OBJECTIVE: To determine the outcome, pattern(s) of failure, and optimal treatment volume in Stage IIIC endometrial carcinoma patients treated with surgery and postoperative radiation therapy (RT).
  • One EFRT patient also underwent concomitant whole-abdominal RT (WART).
  • Adjuvant vaginal brachytherapy (VB) was delivered in 10, chemotherapy in 5, and hormonal therapy in 7 patients.
  • No patient developed an isolated abdominal recurrence.
  • Two patients developed significant RT sequelae: chronic diarrhea in 1 patient treated with WPRT and VB, and small bowel obstruction in 1 patient treated with EFRT.
  • The low rate of abdominal recurrence does not support the routine use of WART in these women.
  • Given the predominance of failure in distant sites, attention should be focused on the development of systemic chemotherapy protocols.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Chicago / epidemiology. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Papillary / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483324.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


43. El Ghelbazouri N, Afifi Y, Benameur H, Bella A, Elhallaoui Y, Kettani F, Aït Ourhrouil M, Senouci K, Hassam B: [Oral verrucous carcinoma and human papillomavirus infection]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):659-62
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient died a few days before the start of preoperative chemotherapy following severe deterioration of her general state.
  • It appears as a wart-like exophytic lesion and progresses over several years.
  • Management and treatment are not codified but surgery remains the treatment of choice and relapse is common in the case of locoregional involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925690.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. Kimberlin DW: Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res; 2004 Sep;63(3):141-51
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis.
  • JO-RRP is the second most common cause of hoarseness among pediatric patients, and is the most common benign neoplasm in the larynx.
  • The traditional treatment for JO-RRP is the physical removal of the wart through laryngoscopy and surgical debulking of the airway papillomas.
  • Papillomas frequently recur following surgical resection, however, often necessitating repeated ablative efforts to maintain a patent airway.
  • In a minority of patients, surgical management must be supplemented with adjuvant medical therapy, with interferon being the best studied and most commonly utilized.
  • Recently, a Phase II investigation of a therapeutic vaccine yielded promising results, and a Phase III evaluation of this therapeutic modality is planned.
  • Other adjuvant treatments currently being utilized, but for which controlled data of benefit are lacking, include cidofovir, indole-3-carbinol, ribavirin, mumps vaccine, and photodynamic therapy.
  • As with surgical management, viral persistence occurs following treatment with these adjuvant modalities, further contributing to the challenge of managing patients with this potentially devastating disease.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15451182.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI-15113; United States / NIAID NIH HHS / AI / N01-AI62554; United States / NCRR NIH HHS / RR / RR-032
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 103
  •  go-up   go-down


45. Nguyen NP, Sallah S, Karlsson U, Vos P, Ludin A, Semer D, Tait D, Salehpour M, Jendrasiak G, Robiou C: Prognosis for papillary serous carcinoma of the endometrium after surgical staging. Int J Gynecol Cancer; 2001 Jul-Aug;11(4):305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients with advanced disease received chemotherapy only.
  • Two patients with early-stage disease were followed without further treatment.
  • Eighteen patients received postoperative irradiation; eight patients received whole abdominal irradiation (WART), and the remaining 10 patients, pelvic irradiation (PRT).
  • RESULTS: Seven patients (32%) developed distant metastases, three out of seven (42%) after WART.
  • Four out of seven patients who had distant metastases died from disease progression during subsequent chemotherapy.
  • Four patients with pelvic recurrences developed concurrent (2) and subsequent (2) distant metastases.
  • CONCLUSION: Pathological staging should be performed for all patients with UPSC to determine the prognosis as well as to tailor the treatment.
  • The role of abdominal irradiation in the treatment of UPSC is yet to be determined; however, such an approach may not be necessary for the control of disease for patients with early-stage (I and II) disease.
  • Patients with locally advanced-stage (stage III) disease are at risk of local regional failures and distant metastases despite WART.
  • Therefore, the benefit of WART for advanced-stage disease is also questionable.
  • Paclitaxel-based chemotherapy is currently being investigated in this setting.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. North Carolina. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520370.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A: A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol; 2007 Nov;21(10):1404-12
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.
  • DESIGN: Randomized, double-blind, placebo-controlled study for up to 12 weeks with a 12-week treatment-free follow-up.
  • PATIENTS: Two hundred forty-two outpatients (125 men, 117 women) with 2 to 30 warts (total wart area, 12-600 mm(2)).
  • Intervention(s) Topical application of Polyphenon E 10% Cream, Polyphenon E 15% Ointment or placebo to all external genital warts three times a day.
  • MAIN OUTCOME MEASURE(S): Measurement of total wart area and local reactions/adverse events.
  • Recurrence rates 12 weeks after end of treatment were 10.6%, 11.8% and 10.3% for 15% ointment, 10% cream and placebo, respectively.
  • Local skin reactions were generally mild to moderate and resolved with continued treatment without sequelae.
  • CONCLUSIONS: Polyphenon(R) E 15% ointment, composed of a defined green tea extract, proved to be efficacious and safe for both gender in the treatment of external genital warts.
  • [MeSH-major] Catechin / analogs & derivatives. Condylomata Acuminata / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Double-Blind Method. Female. Humans. Logistic Models. Male. Middle Aged. Ointments. Placebos. Prognosis. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17958849.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ointments; 0 / Placebos; 0 / polyphenon E; 8R1V1STN48 / Catechin
  •  go-up   go-down


47. Vilata JJ, Badia X, ESCCRIM group: Effectiveness, satisfaction and compliance with imiquimod in the treatment of external anogenital warts. Int J STD AIDS; 2003 Jan;14(1):11-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness, satisfaction and compliance with imiquimod in the treatment of external anogenital warts.
  • This study aims to evaluate the effectiveness of imiquimod treatment of external anogenital warts and analyse its possible relationship with patient treatment satisfaction and compliance under conditions of routine clinical practice.
  • Imiquimod 5% cream was administered three times a week until the end of treatment (complete wart clearance or up to a maximum of 16 weeks).
  • Effectiveness and compliance were evaluated at four weeks and again at the end of treatment, when satisfaction was also assessed.
  • Complete wart clearance was experienced by 66.6% of patients at the end of treatment and a 50% or greater reduction in total wart area occurred in 79.5%.
  • Imiquimod was more effective in patients who were more satisfied and compliant with treatment.
  • Under conditions of routine clinical practice, imiquimod is an effective treatment for external anogenital warts.
  • [MeSH-major] Aminoquinolines / therapeutic use. Condylomata Acuminata / drug therapy. Patient Compliance
  • [MeSH-minor] Adult. Humans. Interferon Inducers. Male. Ointments / administration & dosage. Prospective Studies. Treatment Outcome. Vaginal Creams, Foams, and Jellies

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12590786.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Interferon Inducers; 0 / Ointments; 0 / Vaginal Creams, Foams, and Jellies; 99011-02-6 / imiquimod
  •  go-up   go-down


48. Duan J, Paris W, De Marte J, Roopchand D, Fleet TL, Cordingley MG: Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence. Antiviral Res; 2000 May;46(2):135-44
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence.
  • The present study examined topical effects of cidofovir on cutaneous rabbit warts.
  • Inoculation with 50 ID(50) induced papillomas at 100% of the inoculation sites within 16+/-1 days, and the wart growth curve plateaued within approximately 7 weeks.
  • With an inoculum of 5 ID(50), 80% of the inoculated sites developed papillomas within 21+/-1 days and their size plateaued at a later time.
  • Cidofovir was applied topically twice daily on the inoculated sites at a concentration of 1% for 18 days, starting at three different time points.
  • In the first experiment, treatment was initiated 7 days post-inoculation.
  • With this treatment regimen, cidofovir significantly delayed the time of onset and the growth rate of papillomas induced with the high titer of inoculum.
  • It completely prevented papilloma-induction on the sites inoculated with the low titer of CRPV.
  • Both therapeutic and side-effects were limited to the sites of direct exposure.
  • With this treatment regimen, cidofovir significantly reduced wart growth against the low titer only.
  • Topical treatment initiated on day 49 post-inoculation was not effective on warts initiated with either viral titer.
  • These results demonstrated that topical cidofovir could be very effective against papillomavirus-induced wart growth if it is initiated early during the infection, especially against low titers of inoculum.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cottontail rabbit papillomavirus. Cytosine / analogs & derivatives. Organophosphonates. Organophosphorus Compounds / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Animals. Disease Models, Animal. Drug Evaluation, Preclinical. Female. Rabbits. Time Factors

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854665.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


49. Gladsjo JA, Alió Sáenz AB, Bergman J, Kricorian G, Cunningham BB: 5% 5-Fluorouracil cream for treatment of verruca vulgaris in children. Pediatr Dermatol; 2009 May-Jun;26(3):279-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5% 5-Fluorouracil cream for treatment of verruca vulgaris in children.
  • Warts are a common pediatric skin disease.
  • Most treatments show only modest benefit, and some are poorly tolerated because of pain.
  • Efficacy, safety, and tolerability of topical 5% 5-fluorouracil for treatment of common warts were examined in an open-label pilot study with pediatric patients.
  • Assessment of treatment response and side effects was performed at baseline, treatment completion, and 3- and 6-month follow-ups.
  • Hematology measures, liver function tests, and medication blood levels were reassessed at treatment completion.
  • Eighty-eight percent of treated warts improved after 6 weeks of treatment, and 41% of subjects had complete resolution of at least one wart.
  • Treatment response did not differ between once or twice daily applications.
  • At 6 month follow-up, 87% of complete responders had no wart recurrence.
  • Topical 5% 5-fluorouracil is a safe, effective, and well-tolerated treatment for warts in children.
  • [MeSH-major] Antimetabolites / administration & dosage. Fluorouracil / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Adolescent. Child. Child, Preschool. Hand Dermatoses / drug therapy. Humans. Ointments

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706088.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Ointments; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C: Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol; 2008 Jun;158(6):1329-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.
  • BACKGROUND: Benign external genital and perianal warts (condylomata acuminata) are disfiguring, displeasing skin tumours caused by human papillomavirus that may vitally burden affected patients and their partners.
  • Current treatment options are still unsatisfactory due to low efficacy, high recurrence rates or an unfavourable side-effect profile.
  • Although most recently prophylactic vaccines have been recommended for adolescent women, appropriate treatment modalities for anogenital warts are still needed.
  • Polyphenon E (MediGene AG, Munich, Germany), a proprietary extract of green tea leaves, was therefore investigated for the topical treatment of this frequent viral disease.
  • OBJECTIVES: To investigate Polyphenon E 15% and 10% ointment for efficacy and safety in the treatment of anogenital warts in immunocompetent men and women.
  • The topical treatment was self-applied by the patients three times daily to all warts.
  • Recurrence was evaluated during a 12-week treatment-free follow-up period for patients with complete clearance.
  • Time to complete clearance was comparable for both strengths of Polyphenon E ointment.
  • About 78% of all patients treated with either Polyphenon E 15% or 10% ointment showed wart clearance rates of 50% or better.
  • Less than 6% and 4% of patients in the Polyphenon E 15% and 10% ointment groups experienced wart recurrence during follow-up.
  • Local reactions declined during continued treatment.
  • CONCLUSIONS: The results indicate that Polyphenon E ointment is an efficacious and safe patient-applied topical treatment for external genital and perianal warts.
  • [MeSH-major] Catechin / analogs & derivatives. Condylomata Acuminata / drug therapy. Genital Diseases, Female / drug therapy. Genital Diseases, Male / drug therapy. Papillomavirus Infections / drug therapy. Phytotherapy
  • [MeSH-minor] Administration, Cutaneous. Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Plant Preparations / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363746.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Preparations; 0 / polyphenon E; 8R1V1STN48 / Catechin
  •  go-up   go-down


51. Marelli G, Papaleo E, Origoni M, Caputo L, Ferrari A: Polyhexamethylene biguanide for treatment of external genital warts: a prospective, double-blind, randomized study. Eur Rev Med Pharmacol Sci; 2005 Nov-Dec;9(6):369-72
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyhexamethylene biguanide for treatment of external genital warts: a prospective, double-blind, randomized study.
  • The present prospective, double-blind, randomized, placebo (vehicle-controlled) trial evaluated the efficacy and safety of daily patient-applied polyhexamethylene biguanide for up to 16-weeks for the treatment of external genital warts.
  • Wart recurrence was investigated during a 12-week treatment-free follow-up period.
  • There were no systemic reactions, although local skin reactions (generally of mild or moderate severity) were common in the polyhexamethylene biguanide cream group.
  • Local reactions caused two patients to discontinue treatment.
  • The most frequently reported local skin reactions were erythema, excoriation or flaking, and erosion.
  • Patient-applied polyhexamethylene biguanide cream is effective for the treatment of external genital warts and has a favorable safety profile.
  • [MeSH-major] Biguanides / therapeutic use. Condylomata Acuminata / drug therapy. Disinfectants / therapeutic use
  • [MeSH-minor] Administration, Cutaneous. Administration, Topical. Adult. Double-Blind Method. Erythema / chemically induced. Female. Humans. Male. Ointments. Prospective Studies. Pruritus / chemically induced. Recurrence. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479742.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biguanides; 0 / Disinfectants; 0 / Ointments; 28757-47-3 / polyhexamethylene biguanide
  •  go-up   go-down


52. Sauder DN, Skinner RB, Fox TL, Owens ML: Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis; 2003 Feb;30(2):124-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations.
  • GOAL: The aim of this analysis was to determine whether patients' demographic variables affect the efficacy of imiquimod 5% cream versus vehicle cream for the treatment of external genital and perianal warts.
  • STUDY DESIGN: Male and female immunocompetent patients applied imiquimod 5% cream topically to external genital warts 3 times a week until wart clearance or for up to 16 weeks.
  • We have examined the clearance rates for subgroups based on variables of gender, baseline wart area, duration of current outbreak of warts, previous wart treatment, and tobacco use.
  • CONCLUSION: Imiquimod 5% cream is an effective treatment for external genital and perianal warts and provides a significant benefit in comparison with vehicle cream, independent of gender, initial wart size, duration of current outbreak of warts, previous wart treatment, or tobacco use.
  • [MeSH-major] Aminoquinolines / administration & dosage. Condylomata Acuminata / drug therapy. Genital Diseases, Female / drug therapy. Genital Diseases, Male / drug therapy. Interferon Inducers / administration & dosage
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Double-Blind Method. Female. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12567169.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


53. Pervaiz S: Resveratrol--from the bottle to the bedside? Leuk Lymphoma; 2001 Feb;40(5-6):491-8
Hazardous Substances Data Bank. RESVERATROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More recently, since the first report on the apoptosis inducing activity of resveratrol in human cancer cells, the interest in this molecule as a potential chemotherapy agent has significantly intensified.
  • Our group has been active in studying the cross talk between the caspase family of proteases and mitochondria, in drug-induced apoptosis.
  • The cytotoxicity of resveratrol is restricted against these transformed cell types due to its ability to selectively upregulate CD95-CD95L interaction on the tumor cell surface, unlike normal peripheral blood cells.
  • We also extrapolate these in vitro findings in a murine model of carcinogensis, and demonstrate in vivo induction of apoptosis in mouse skin papillomas.
  • [MeSH-minor] Antigens, CD95. Apoptosis / drug effects. Fas Ligand Protein. Humans. Membrane Glycoproteins. Neoplasms / drug therapy. Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426522.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents, Phytogenic; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; 0 / Stilbenes; Q369O8926L / resveratrol
  • [Number-of-references] 58
  •  go-up   go-down


54. Stender IM, Na R, Fogh H, Gluud C, Wulf HC: Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet; 2000 Mar 18;355(9208):963-6
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial.
  • BACKGROUND: Photodynamic therapy (PDT) with topical 5-aminolaevulinic acid (ALA) followed by irradiation with incoherent light (ALA-PDT) for recalcitrant warts have had beneficial results.
  • METHODS: Recalcitrant foot and hand warts were randomly assigned to six repetitive ALA-PDT or placebo-PDT interventions combined with standard treatment encompassing paring followed by a keratolytic (Verucid).
  • Standardised photographs of each wart were taken before, during (week 7) and after treatment (weeks 14 and 18).
  • The area of each wart compared with entry area was the primary outcome variable, measured from photographs by an evaluator unaware of treatment allocation for intervention.
  • In week 14, the median relative reduction in wart area was 98% in the ALA-PDT group (interquartile range 100%, 55%) versus 52% (100%, 0) in the placebo group (p=0.0006).
  • In week 18, the median relative reduction in wart area was 100% in the ALA-PDT group (100%, 57%) versus 71% (100%, 0) in the placebo-PDT arm (p=0.008).
  • Both the number of vanishing warts and the difference in relative wart area of persisting warts at week 14 and 18 were significant (p<0.05) in favour of ALA-PDT.
  • Significantly more ALA-PDT warts were graded at a higher pain intensity after treatment than placebo-PDT warts.
  • INTERPRETATION: ALA-PDT is superior to placebo-PDT when both wart area and number of vanishing warts are considered.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Foot Diseases / drug therapy. Hand. Photochemotherapy. Photosensitizing Agents / therapeutic use. Warts / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Double-Blind Method. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10768434.001).
  • [ISSN] 0140-6736
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


55. Yazdanfar A, Farshchian M, Fereydoonnejad M, Farshchian M: Treatment of common warts with an intralesional mixture of 5-fluorouracil, lidocaine, and epinephrine: a prospective placebo-controlled, double-blind randomized trial. Dermatol Surg; 2008 May;34(5):656-9
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of common warts with an intralesional mixture of 5-fluorouracil, lidocaine, and epinephrine: a prospective placebo-controlled, double-blind randomized trial.
  • BACKGROUND: 5-Fluorouracil is an antimetabolite that has been known to be effective for the treatment of common warts.
  • OBJECTIVE: The objective was to evaluate the efficacy of a combination of 5-fluorouracil, lidocaine, and epinephrine (5-FU+LE) for the treatment of common warts.
  • The selected warts were randomized into two treatment groups, with one wart on each patient receiving intralesional 5-FU+LE (4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine) and the other receiving intralesional normal saline placebo using a Mantoux needle.
  • Systemic reaction or treatment-related adverse medical events and recurrence rate did not differ significantly between two groups.
  • [MeSH-major] Antimetabolites / administration & dosage. Epinephrine / administration & dosage. Fluorouracil / administration & dosage. Lidocaine / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Adolescent. Adult. Double-Blind Method. Drug Therapy, Combination. Female. Humans. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. LIDOCAINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261100.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 98PI200987 / Lidocaine; U3P01618RT / Fluorouracil; YKH834O4BH / Epinephrine
  •  go-up   go-down


56. Liu YX, Zheng HY, Liu XR: 5-aminolaevulinic acid-photodynamic therapy for the treatment of cervical condylomata acuminata. Chin Med Sci J; 2009 Sep;24(3):151-5
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-aminolaevulinic acid-photodynamic therapy for the treatment of cervical condylomata acuminata.
  • OBJECTIVE: To investigate the efficacy and safety of photodynamic therapy (PDT) with topical 5-aminolaevulinic acid (ALA) on cervical condylomata acuminata.
  • The treatment was repeated 7 days later if the lesion was not completely removed after the first treatment.
  • Complete response rate and recurrence rate of wart lesions as well as rate of adverse reaction were analyzed.
  • CONCLUSION: Compared with conventional therapies, topical application of ALA-PDT is a simple, effective, safe, well-tolerated, and low recurrence rate treatment for cervical condylomata acuminata.

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19848315.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


57. Wang YS, Tay YK, Kwok C, Tan E: Photodynamic therapy with 20% aminolevulinic acid for the treatment of recalcitrant viral warts in an Asian population. Int J Dermatol; 2007 Nov;46(11):1180-4
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with 20% aminolevulinic acid for the treatment of recalcitrant viral warts in an Asian population.
  • BACKGROUND: Topical photodynamic therapy (PDT) is based on the principle of targeted tissue destruction using selective photosensitization via a topical porphyrin precursor, followed by light exposure.
  • It is well established for the treatment of actinic keratoses and superficial nonmelanoma skin cancers.
  • METHODS: We carried out a prospective, single-arm, phase II study of 5-aminolevulinic acid (5-ALA)-PDT in the treatment of recalcitrant viral warts in an Asian population.
  • PDT was repeated fortnightly for a maximum of four times.
  • They had skin phototypes III-IV.
  • Nine patients had plantar warts and three patients had hand warts (two had warts on the fingers, one had a wart on the palm).
  • Five patients (42%) showed complete disappearance of their warts, one patient (8%) showed partial clearance (greater than 50% decrease in the wart area), five patients (42%) had stable disease (less than 50% decrease in the wart area), and one (8%) showed progressive disease (increase in the wart area).
  • CONCLUSION: 5-ALA-PDT, given its noninvasiveness, minimal adverse effects, and good cosmetic results, is a promising alternative treatment for recalcitrant viral warts.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Foot Dermatoses / drug therapy. Hand Dermatoses / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988339.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


58. Khattar JA, Musharrafieh UM, Tamim H, Hamadeh GN: Topical zinc oxide vs. salicylic acid-lactic acid combination in the treatment of warts. Int J Dermatol; 2007 Apr;46(4):427-30
Hazardous Substances Data Bank. SALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical zinc oxide vs. salicylic acid-lactic acid combination in the treatment of warts.
  • Treatment is painful, prolonged, and can cause scarring.
  • OBJECTIVE: To evaluate topical zinc oxide for the treatment of warts.
  • No patients developed serious side-effects.
  • CONCLUSION: Topical zinc oxide is an efficacious, painless, and safe therapeutic option for wart treatment.
  • [MeSH-major] Dermatologic Agents / administration & dosage. Skin Diseases, Viral / drug therapy. Warts / drug therapy. Zinc Oxide / administration & dosage
  • [MeSH-minor] Administration, Cutaneous. Adolescent. Adult. Double-Blind Method. Drug Therapy, Combination. Female. Humans. Lactic Acid / administration & dosage. Male. Middle Aged. Ointments. Salicylic Acid / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. ZINC OXIDE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442091.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Ointments; 33X04XA5AT / Lactic Acid; O414PZ4LPZ / Salicylic Acid; SOI2LOH54Z / Zinc Oxide
  •  go-up   go-down


59. Pollock B, Sheehan-Dare R: Pulsed dye laser and intralesional bleomycin for treatment of resistant viol hand warts. Lasers Surg Med; 2002;30(2):135-40
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulsed dye laser and intralesional bleomycin for treatment of resistant viol hand warts.
  • BACKGROUND AND OBJECTIVE: Viral warts affect 7-10% of the population and are a major burden on time and resources of dermatology departments everywhere.
  • Some warts prove resistant to multiple therapies, and this is particularly common in the immunosuppressed patient.
  • Numerous treatments are available, but no one treatment has emerged as the treatment of choice.
  • Four subjects were on long-term immunosuppressant drugs.
  • Area of the wart was anaesthetized with 1% lignocaine, then treated with a pulsed dye laser (7 mm spot, fluence 10 J/cm2).
  • Immediately following this bleomycin (0.5 IU/ml) was injected into the base of the wart.
  • Monthly follow-up and treatment until satisfactory clearance.
  • The remaining two warts responded partially to two treatments, but the patient was happy with the result and did not wish further treatment.
  • CONCLUSIONS: The initial treatment of the wart with pulsed dye laser serves to "prepare" the wart for the bleomycin injection, which can then be given very easily.
  • This ensures the drug is deposited into the base of the wart where it is most needed and minimises the risk of infiltration of normal skin or the operative environment.
  • This method of combining pulsed dye laser and intralesional bleomycin appears to be a safe, rapid, well tolerated, and successful treatment for resistant hand warts.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bleomycin / therapeutic use. Dermatologic Agents / therapeutic use. Hand / surgery. Laser Therapy / methods. Warts / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Drug Resistance, Viral. Female. Follow-Up Studies. Humans. Injections, Intralesional. Male. Middle Aged. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11870793.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Dermatologic Agents; 11056-06-7 / Bleomycin
  •  go-up   go-down


60. Schroeter CA, Kaas L, Waterval JJ, Bos PM, Neumann HA: Successful treatment of periungual warts using photodynamic therapy: a pilot study. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1170-4
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of periungual warts using photodynamic therapy: a pilot study.
  • AIM: The aim of this pilot study was an investigation on photodynamic therapy (PDT) whether it is a good alternative for treating periungual and subungual warts of the hands.
  • After a mean incubation time of 4.6 h (SD: 1.2), the warts were irradiated with the VersaLight for 5-30 min (15.2 +/- 4.3 min).
  • RESULTS: After a mean of 4.5 treatments a mean clearance of 100% was achieved in 90% of the patients.
  • The subungual or periungual location of the wart had no influence on the number of treatments or end result (P > 0.05).
  • Besides mainly pain and hyperpigmentation, most treatments had no side-effects.
  • [MeSH-major] Hand Dermatoses / drug therapy. Photochemotherapy / methods. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aminolevulinic Acid / administration & dosage. Child. Female. Humans. Male. Middle Aged. Photosensitizing Agents / administration & dosage. Pilot Projects. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894700.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


61. Chadha NK, James AL: Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev; 2005;(4):CD005053
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant antiviral therapy for recurrent respiratory papillomatosis.
  • BACKGROUND: Recurrent respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the upper airway.
  • Treatment usually involves repeated surgical debulking of the papillomata, and several agents have been proposed as adjuvants to surgical debulking.
  • OBJECTIVES: To assess the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children and adults.
  • AUTHORS' CONCLUSIONS: There was insufficient evidence from controlled trials on which to base reliable conclusions about the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis.
  • Further research is required before any specific antiviral adjuvant therapy can be recommended.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Airway Obstruction / drug therapy. Airway Obstruction / virology. Chemotherapy, Adjuvant. Child. Humans. Recurrence

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2010;(1):CD005053 [20091568.001]
  • (PMID = 16235390.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 19
  •  go-up   go-down


62. Jiang Y, Wan K, Wang C, Wang P, Chen Y, Zeng X, Zhang S: [Experimental and clinical research on the effect of keyouling on condyloma acuminatum and adjustment of cellular immunity function]. Zhonghua Nan Ke Xue; 2004 Jan;10(1):67-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To discuss the mechanism of the traditional Chinese medicine Keyouling oral liquid in the treatment of condyloma acuminatum(CA) and the adjustment of cellular immunity function.
  • METHODS: The IL-18 and TNF-alpha levels of peripheral serum and wart tissue of patterned rats and CA patients exposed to Keyouling were determined by means of double-antibody sandwich ELISA, and the NK cellular activity of the spleen of the patterned rats and that of the peripheral blood of the CA patients exposed to Keyouling were determined by means of 3H-TdR isotype release.
  • RESULTS: The IL-18 and TNF-alpha levels, the NK cellular activity of the high-dosage group showed significant difference from those of the pattern group and low-dosage group in animal experiment(P < 0.05); the IL-18 and TNF-alpha levels of peripheral serum and wart tissues, and the NK cellular activity of the peripheral blood of the treatment group showed significant difference from those of the control group after treatment(P < 0.01, P < 0.05).
  • [MeSH-major] Condylomata Acuminata / drug therapy. Medicine, Chinese Traditional
  • [MeSH-minor] Adolescent. Adult. Animals. Female. Humans. Interleukin-18 / blood. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Male. Middle Aged. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14979213.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


63. Matteelli A, Beltrame A, Graifemberghi S, Forleo MA, Gulletta M, Ciravolo G, Tedoldi S, Casalini C, Carosi G: Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis; 2001 Jun;28(6):343-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons.
  • BACKGROUND: Treatment options for anogenital warts in patients with HIV-1 are unsatisfactory because they fail to eradicate latent human papillomavirus.
  • GOAL: To determine tolerability and efficacy of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected patients.
  • Thus, 12 treatment rounds of cidofovir were compared with six rounds of placebo.
  • A reduction of more than 50% in the total wart area achieved by seven cidofovir treatments (58%), as compared with no placebo regimen (P = 0.02).
  • [MeSH-major] Antiviral Agents / therapeutic use. Anus Diseases / drug therapy. Cytosine / therapeutic use. Female Urogenital Diseases / drug therapy. HIV Infections / complications. Male Urogenital Diseases. Organophosphonates. Organophosphorus Compounds / therapeutic use. Tumor Virus Infections / drug therapy. Warts / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Adult. Female. Humans. Male. Patient Satisfaction. Pilot Projects. Single-Blind Method. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11403192.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


64. Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, He Q, Wolff JC: Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatol Venereol; 2007 Sep;21(8):1054-60
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
  • OBJECTIVE: To evaluate the efficacy of 5% imiquimod in HIV-positive male patients with anogenital warts or anal intraepithelial neoplasia (AIN), and to elucidate whether human papillomavirus (HPV) type and viral load were important for clinical outcome and recurrences.
  • Topical 5% imiquimod was applied three times per week for more than 8 h overnight for 16 weeks, although patients were allowed to continue therapy for 4 more weeks if they did not have complete clearance of lesions.
  • Main HPV types detected corresponded to low-risk HPV types.
  • At 20 weeks of therapy, 46% patients achieved total clearance whereas 14 patients had > 50% clearance.
  • Clearance was not influenced by patients' CD4 counts, wart location, HIV viral load or HPV viral load.
  • CONCLUSIONS: The assumption that visible perianal warts are benign lesions in HIV-positive patients has to be reevaluated since an important number of such lesions could correspond to low-grade anal disease, which in turn could progress to high-grade anal disease or cancer.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Anus Diseases / drug therapy. Anus Neoplasms / drug therapy. Condylomata Acuminata / drug therapy. Genital Diseases, Male / drug therapy. Papillomavirus Infections / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Carcinoma in Situ / drug therapy. Carcinoma in Situ / virology. Humans. Male. Middle Aged. Papillomaviridae / classification. Polymerase Chain Reaction. Treatment Outcome. Viral Load


65. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ: Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis; 2005 Dec 15;192(12):2099-107
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
  • BACKGROUND: Cellular immunity is involved in spontaneous clearance of anogenital warts caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept of therapeutic vaccination.
  • A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts.
  • Three doses of vaccine or placebo were administered along with either ablative therapy or podophyllotoxin.
  • RESULTS: Although a positive trend toward clearance was seen in patients infected with only HPV-6, in neither substudy did the vaccine significantly increase the efficacy of conventional therapies, despite induction of adequate immune responses.
  • Extensive HPV typing by polymerase chain reaction demonstrated that a majority of screened subjects (73.7%) were infected with HPV-6 and/or HPV-11 and that a large proportion (40.1%) were infected with multiple HPV types.
  • HPV types that put subjects at high risk of development of cervical cancer were detected in 39.8% of subjects.
  • CONCLUSIONS: Infection with multiple HPV types, including high-risk types, is common in anogenital wart disease.
  • Therapeutic vaccination failed to increase the efficacy of conventional therapies.
  • [MeSH-major] Capsid Proteins / immunology. Condylomata Acuminata / therapy. Condylomata Acuminata / virology. Human papillomavirus 6 / immunology. Oncogene Proteins, Viral / immunology. Papillomaviridae / classification. Papillomavirus Vaccines. Vaccines, Synthetic / therapeutic use. Viral Vaccines / therapeutic use
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adolescent. Adult. DNA, Viral / genetics. DNA, Viral / isolation & purification. Double-Blind Method. Drug Combinations. Female. Genotype. Humans. Lipid A / administration & dosage. Lipid A / analogs & derivatives. Lipid A / pharmacology. Male. Middle Aged. Placebos. Podophyllotoxin / administration & dosage. Polymerase Chain Reaction. Saponins / administration & dosage. Saponins / pharmacology

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288373.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASO2A adjuvant; 0 / Adjuvants, Immunologic; 0 / Capsid Proteins; 0 / DNA, Viral; 0 / Drug Combinations; 0 / L2 oncogene viral capsid protein, Human papillomavirus type 6; 0 / Lipid A; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus Vaccines; 0 / Placebos; 0 / Saponins; 0 / Vaccines, Synthetic; 0 / Viral Vaccines; 0 / oncogene protein E7, Human papillomavirus type 6; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


66. Horn TD, Johnson SM, Helm RM, Roberson PK: Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol; 2005 May;141(5):589-94
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial.
  • Destructive modalities are generally the first physician-administered therapy.
  • Other treatment options include immunotherapy.
  • Intralesional immunotherapy using mumps, Candida, or Trichophyton skin test antigens has proved efficacy in the treatment of warts.
  • OBJECTIVES: To determine rates of wart resolution in response to injection of antigen alone, antigen plus interferon alfa-2b, interferon alfa-2b alone, and normal saline; and to compare response according to viral type, major histocompatibility complex antigens, and peripheral blood mononuclear cell proliferation to autologous human papillomavirus antigen before and after injection.
  • RESULTS: Responders were observed in all treatment arms, but were significantly more likely to have received antigen (P<.001).
  • No viral type or major histocompatibility complex antigen correlated with response or lack of response (P>.99 and P = .86, respectively).
  • A positive peripheral blood mononuclear cell proliferation assay result (2 times pretreatment levels) was significantly more likely among responders (P = .002).
  • CONCLUSIONS: Intralesional immunotherapy using injection of Candida, mumps, or Trichophyton skin test antigens is an effective treatment for warts, as indicated by significantly higher response rates and distant response rates in subjects receiving antigen.
  • Viral type and major histocompatibility complex antigens did not seem to influence treatment response.
  • Response is accompanied by proliferation of peripheral blood mononuclear cells to human papillomavirus antigens, suggesting that a human papillomavirus-directed cell-mediated immune response plays a role in wart resolution.
  • [MeSH-major] Antigens, Fungal / administration & dosage. Antigens, Viral / administration & dosage. Candida / immunology. Immunotherapy / methods. Mumps virus / immunology. Trichophyton / immunology. Warts / therapy
  • [MeSH-minor] Adult. Antiviral Agents / adverse effects. Antiviral Agents / therapeutic use. Cell Division / drug effects. Female. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Histocompatibility Antigens / blood. Humans. Injections, Intralesional. Interferon-alpha / adverse effects. Interferon-alpha / therapeutic use. Male. Monocytes / pathology. Papillomaviridae / immunology. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Mumps.
  • MedlinePlus Health Information. consumer health - Warts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897380.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR14288
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Fungal; 0 / Antigens, Viral; 0 / Antiviral Agents; 0 / Histocompatibility Antigens; 0 / Interferon-alpha; 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


67. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR: Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol; 2008 Jun;111(6):1371-9
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.
  • OBJECTIVE: To estimate the clinical efficacy of topical sinecatechins, a defined green tea extract, in the treatment of external genital and perianal warts.
  • METHODS: This was a randomized, double-blind, vehicle-controlled trial involving 502 male and female patients aged 18 years and older, with 2-30 anogenital warts ranging from 12 to 600 mm(2) total wart area.
  • Patients applied sinecatechins ointment 15% or 10% or vehicle (placebo) three times daily for a maximum of 16 weeks or until complete clearance of all warts, followed by a 12-week treatment-free follow-up to assess recurrence.
  • During follow-up, recurrence of any wart was observed in 6.5%, 8.3%, and 8.8% in the sinecatechins ointment 15% group, sinecatechins ointment 10% group, and vehicle patients, respectively.
  • A total of 3.7%, 8.3%, and 0.0% developed new warts, respectively.
  • CONCLUSION: Topical sinecatechins ointments 15% and 10% are effective and well-tolerated in the treatment of anogenital warts.
  • [MeSH-major] Anus Diseases / drug therapy. Catechin / therapeutic use. Condylomata Acuminata / drug therapy. Genital Diseases, Female / drug therapy. Genital Diseases, Male / drug therapy. Tea
  • [MeSH-minor] Adolescent. Adult. Aged. Double-Blind Method. Female. Humans. Male. Middle Aged. Ointments. Plant Extracts / administration & dosage. Plant Extracts / therapeutic use. Recurrence. Treatment Outcome


68. Xie FM, Zeng K, Chen ZL, Li GF, Lin ZF, Zhu XL, Sun LD: [Treatment of recurrent condyloma acuminatum with solid lipid nanoparticle gel containing podophyllotoxin: a randomized double-blinded, controlled clinical trial]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 May;27(5):657-9
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of recurrent condyloma acuminatum with solid lipid nanoparticle gel containing podophyllotoxin: a randomized double-blinded, controlled clinical trial].
  • OBJECTIVE: To observe the clinical efficacy and safety of podophyllotoxin delivered via solid lipid nanoparticle gel for topic treatment of recurrent condyloma acuminatum.
  • METHODS: In a randomized double-blinded study, podophyllotoxin solid lipid nanoparticles gel and routine podophyllotoxin gel preparation was applied respectively for treatment of 97 volunteer patients with recurrent condyloma acuminatum.
  • The therapeutic effect, condyloma acuminatum relapse following the treatment and adverse effect were evaluated.
  • RESULTS: The wart clearance rate in the condyloma acuminatum patients in the first treatment course with podophyllotoxin solid lipid nanoparticle gel reached 97.1%, close to that with the routine preparation of 90.6%, but the nanoparticle preparation significantly reduced the recurrence rate and adverse effect (P<0.01).
  • [MeSH-major] Condylomata Acuminata / drug therapy. Lipids / chemistry. Nanoparticles / chemistry. Podophyllotoxin / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Double-Blind Method. Drug Delivery Systems. Female. Gels. Humans. Male. Middle Aged. Secondary Prevention. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545082.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Gels; 0 / Lipids; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


69. Isçimen A, Aydemir EH, Göksügür N, Engin B: Intralesional 5-fluorouracil, lidocaine and epinephrine mixture for the treatment of verrucae: a prospective placebo-controlled, single-blind randomized study. J Eur Acad Dermatol Venereol; 2004 Jul;18(4):455-8
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional 5-fluorouracil, lidocaine and epinephrine mixture for the treatment of verrucae: a prospective placebo-controlled, single-blind randomized study.
  • BACKGROUND: The treatment of viral warts remains challenging.
  • A variety of treatment modalities have been used with a range of success.
  • Fluorouracil has been shown to be effective in treating warts but the method of its delivery directly onto the affected tissue has been of little efficacy.
  • We evaluated the safety and efficacy of intralesional 5-fluorouracil in the treatment of verrucae.
  • The mixture of 5-FU (4 cm(3), 50 mg/mL), lidocaine (1 cm(3), 20 mg/mL) and epinephrine (0.0125 mg/mL) was injected into the base of the wart using a mantoux needle.
  • CONCLUSIONS: The results demonstrate that treatment of verrucae with 5-FU + LE mixture is safe and effective.
  • [MeSH-major] Anesthetics, Local / administration & dosage. Antimetabolites / administration & dosage. Epinephrine / administration & dosage. Fluorouracil / administration & dosage. Lidocaine / administration & dosage. Vasoconstrictor Agents / administration & dosage. Warts / drug therapy
  • [MeSH-minor] Adolescent. Adult. Drug Combinations. Humans. Injections, Intralesional. Middle Aged. Recurrence. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. LIDOCAINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196161.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Antimetabolites; 0 / Drug Combinations; 0 / Vasoconstrictor Agents; 98PI200987 / Lidocaine; U3P01618RT / Fluorouracil; YKH834O4BH / Epinephrine
  •  go-up   go-down


70. Johnson SM, Horn TD: Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy. J Drugs Dermatol; 2004 May-Jun;3(3):263-5
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy.
  • There are many treatments available.
  • Intralesional injection of a skin test antigen has been shown to be efficacious at eradicating all warts when only a part of one wart is injected.
  • The aim of this study was to determine whether injection of the combination of Candida albicans, mumps, and Trichophyton skin test antigens was more efficacious than and as safe as single antigen injection.
  • Seventy-one percent of subjects had resolution of their warts with the injection of the combination of skin test antigens in this open label single arm study.
  • [MeSH-major] Antigens, Fungal / administration & dosage. Antigens, Viral / administration & dosage. Immunotherapy, Active. Warts / therapy
  • [MeSH-minor] Adult. Candida albicans / immunology. Drug Therapy, Combination. Female. Humans. Injections, Intralesional. Male. Mumps virus / immunology. Skin Tests. Treatment Outcome. Trichophyton / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15176159.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR14288
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Fungal; 0 / Antigens, Viral
  •  go-up   go-down


71. McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ, Gynecologic Oncology Group: Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. Gynecol Oncol; 2009 Jan;112(1):134-41
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
  • OBJECTIVES: To determine the maximum tolerated dose (MTD) and feasibility of weekly cisplatin and paclitaxel chemotherapy administered concurrently with whole abdominal radiation therapy (WART) in women with high-risk endometrial cancer.
  • Six weekly cycles of chemotherapy were administered with WART in dose level (DL) cohorts of 3 patients in a 3+3 design.
  • All patients were to be treated with 25 Gy to the abdomen and 50.2 Gy to the pelvis.
  • The prescribed radiation therapy was successfully delivered to 32/35 patients.
  • Treatment contributed to the deaths of 2 patients.
  • CONCLUSION: A regimen of cisplatin 25 mg/m(2) and paclitaxel 20 mg/m(2) weekly with WART was determined to be feasible, but is associated with moderate acute and chronic gastrointestinal toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18962846.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA27469
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


72. Mitsuishi T, Iida K, Kawana S: Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin. Eur J Dermatol; 2003 Sep-Oct;13(5):445-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin.
  • Cimetidine has been shown to improve various types of human neoplasms and more recently it has been shown to be effective in treating recalcitrant or multiple viral warts in some reports.
  • We investigated 55 patients with multiple viral warts treated only with oral cimetidine for up to 4 months to examine the efficacy of treatment.
  • The patients were divided into two groups: group A received oral cimetidine (<20 mg/kg/day) and group B received the drug (30 to 40 mg/kg/day).
  • In addition, using real time PCR, we measured mRNA levels of the cytokines interleukin-2 (IL-2), IL-18, and interferon (IFN)-gamma taken from selected punch biopsy specimens before and during treatment.
  • As a result, 34.5% (19/55) of the patients had a dramatic clinical improvement or complete remission (CR) of their viral warts and 23.6% (13/55) of the patients had partial responses (PR) within 4 months of cimetidine therapy.
  • IL-2 and IFN-gamma mRNA levels were significantly increased and IL-18 mRNA levels were decreased in tissues of effectively treated viral warts.
  • Our results show that the higher dose of oral cimetidine was more effective in treating multiple viral warts, that cimetidine activates Th1 cells to produce IL-2 and IFN-c and that their expression correlates with wart remission.
  • These results suggest that cimetidine is an effective treatment for viral warts.
  • In addition, based on the decrease in IL-18 mRNA elicited by the drug, IL-18 might be expressed by keratinocytes infected with HPV.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Cimetidine / administration & dosage. Skin Diseases / drug therapy. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. CIMETIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14693487.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Interleukin-18; 0 / Interleukin-2; 80061L1WGD / Cimetidine; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


73. Gubinelli E, Posteraro P, Cocuroccia B, Girolomoni G: Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatolog Treat; 2003 Sep;14(3):184-8
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermodysplasia verruciformis (EV) is characterized by abnormal genetically-determined susceptibility to widespread and persistent infection of the skin with human papillomaviruses (HPV).
  • Skin malignant changes are very common and occur on sun-exposed areas.
  • Several treatments have been used but without consistent benefit.
  • Recently, retinoids and alpha-interferon, alone or in combination, have been reported to be of value in the therapy of EV lesions.
  • We present the case of a 43-year-old white female affected by EV who developed multiple squamous cell carcinomas in the oral and genital mucosae during the previous four years.
  • Both wart and cancer lesions harbored HPV24 along with the novel putative HPV type FA51.
  • Thereafter, interferon was stopped whereas acitretin therapy was continued, but a new Bowen's disease developed in the perianal region, and the acitretin dose was increased at 0.5 mg/kg per day.
  • At six-month follow-up, only a low number of flat warts persisted, and no clinical signs of cutaneous or mucosal carcinoma were evident.
  • [MeSH-major] Acitretin / therapeutic use. Antiviral Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Epidermodysplasia Verruciformis / drug therapy. Interferon-alpha / therapeutic use. Keratolytic Agents / therapeutic use. Papillomaviridae / isolation & purification. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Recombinant Proteins

  • Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522631.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Keratolytic Agents; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; LCH760E9T7 / Acitretin
  •  go-up   go-down


74. Liang J, Lu XN, Tang H, Zhang Z, Fan J, Xu JH: Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminata: a comparative, randomized clinical trial. Photodermatol Photoimmunol Photomed; 2009 Dec;25(6):293-7
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminata: a comparative, randomized clinical trial.
  • OBJECTIVES: To determine the safety and efficacy of photodynamic therapy (PDT) with topical application of 20% wt/vol aminolevulinic acid hydrochloride (ALA) in the treatment of condylomata acuminata (CA).
  • The treatment was repeated weekly if necessary, but no more than 3 times.
  • The primary efficacy endpoint was the wart clearance rate 1 week after the last treatment.
  • The recurrence rate was evaluated at weeks 4, 8 and 12 after the treatment ended.
  • The clinical response to therapy and adverse effects were recorded.
  • By 1 week after the last treatment, the complete clearance rate was 95.93% in the ALA-PDT group and 100% in CO(2) laser group (P>0.05).
  • CONCLUSION: The results confirmed that topical application of ALA-PDT is a simpler and as effective therapy with a lower incidence of adverse effects in the treatment of CA compared with conventional CO(2) laser therapy.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Condylomata Acuminata / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906163.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


75. Davis MD, Weenig RH, Camilleri MJ: Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. A study of 39 patients and a proposal of diagnostic criteria. Br J Dermatol; 2006 Feb;154(2):287-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Confluent and reticulate papillomatosis (CRP) (Gougerot-Carteaud syndrome) is a disorder that has been characterized in only small cohorts of patients.
  • OBJECTIVES: Better to characterize the clinical and pathological findings of the disorder.
  • METHODS: We retrospectively reviewed the clinical presentation, response to treatment and histological findings of patients presenting to Mayo Clinic (Rochester, MN, U.S.A.) with CRP.
  • RESULTS: The disorder was diagnosed in 39 patients between 1972 and 2003.
  • Mean age at onset of the skin eruption was 15 years (range 8-32); 21 patients (54%) were male; most were white; most (33) presented for reasons of cosmesis; and eight described the rash as mildly pruritic.
  • At presentation, the skin eruption had been present for a mean of 3.1 years (range 3 months-20 years) and had been recalcitrant to treatment, including antifungal treatment.
  • Skin biopsy specimens from 21 patients showed variable degrees of hyperkeratosis, acanthosis and papillomatosis.
  • Minocycline was prescribed for 22 patients, of whom 14 of 18 (78%) had complete clearing of the skin eruption and four (22%) a partial response.
  • The skin eruptions recurred after stopping treatment in six patients.
  • Frequently, the diagnosis is delayed and the disorder not recognized by physicians, including dermatologists.
  • It is important to recognize this disorder, because minocycline therapy is highly effective in most patients.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Minocycline / therapeutic use. Papilloma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antifungal Agents / therapeutic use. Biopsy. Child. Diagnosis, Differential. Female. Humans. Hydroxides. Male. Potassium Compounds. Recurrence. Retrospective Studies. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. POTASSIUM HYDROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2007 Mar;156(3):583-4 [17300258.001]
  • (PMID = 16433798.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Hydroxides; 0 / Potassium Compounds; FYY3R43WGO / Minocycline; WZH3C48M4T / potassium hydroxide
  •  go-up   go-down


76. Zimecki M, Artym J: [Therapeutic properties of proteins and peptides from colostrum and milk]. Postepy Hig Med Dosw (Online); 2005;59:309-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic properties of proteins and peptides from colostrum and milk].
  • The immunotropic properties of these proteins prompted investigators research their potential application in prevention and therapy.
  • LF was tried in the treatment of hepatitis C infection and the intestinal form of graft-versus-host disease (GvHD).
  • The protein hydrolyzates were also protective in diabetic animals, reduced tumor growth, had antihypertensive activity and diminished colicky symptoms in infants.
  • HAMLET, a complex of LA and oleic acid, was effective in patients with cutaneous papillomas.
  • Lysozyme found application in infant formulas, the treatment of periodentitis, and the prevention of tooth decay.
  • In conclusion, preparations derived from milk and colostrum are effective, easily bioaccessible, and safe, finding wide application in prevention and therapy for newborns and adults.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995598.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Caseins; 0 / Milk Proteins; 0 / Peptides; 0 / colostrinine; EC 1.11.1.- / Lactoperoxidase; EC 3.4.21.- / Lactoferrin
  • [Number-of-references] 164
  •  go-up   go-down


77. Atasoy M, Ozdemir S, Aktaş A, Aliağaoğlu C, Karakuzu A, Erdem T: Treatment of confluent and reticulated papillomatosis with azithromycin. J Dermatol; 2004 Aug;31(8):682-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of confluent and reticulated papillomatosis with azithromycin.
  • Confluent and reticulated papillomatosis (CRP) is a relatively rare disorder of unknown origin, mostly affecting young female adults.
  • Skin examination revealed brownish, verrucous, hyperkeratotic, 2 to 5 mm papules, which formed confluent patches and plaques with a reticulate network on the interscapular area.
  • The disease can be rather persistent and resistant to topical therapy.
  • Our case showed a satisfactory response to treatment with azithromycin.
  • Although this treatment is known to be effective in some cases, the action mechanism of azithromycin on CRP is not fully understood.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Azithromycin / therapeutic use. Papilloma / diagnosis. Papilloma / drug therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492444.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 83905-01-5 / Azithromycin
  •  go-up   go-down


78. Buck HW, Fortier M, Knudsen J, Paavonen J: Imiquimod 5% cream in the treatment of anogenital warts in female patients. Int J Gynaecol Obstet; 2002 Jun;77(3):231-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream in the treatment of anogenital warts in female patients.
  • OBJECTIVE: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of anogenital warts in a female population.
  • METHODS: In two open-label studies, female patients with anogenital warts applied imiquimod 5% cream three times a week for up to 16 weeks.
  • Patients could be re-treated with imiquimod 5% cream for up to an additional 16 weeks if their warts recurred or new warts developed during the follow-up period.
  • The treatment period could also be extended for up to an additional 16 weeks if patients only experienced partial clearance during the initial 16-week treatment period.
  • RESULTS: Of the female patients who applied imiquimod 5% cream, 75% (449/600) experienced complete clearance of their warts (treatment failure analysis).
  • This includes 46 patients who experienced total clearance when they applied imiquimod for longer than 16 weeks as their warts had only partially cleared in the initial 16 weeks of therapy.
  • During the 6 months of follow-up after the initial treatment period, 15% of patients had recurrent warts.
  • The most frequently observed local skin reaction was erythema.
  • CONCLUSION: In these studies, imiquimod 5% cream was an effective and well-tolerated treatment for anogenital warts in females and continued to be safe and effective in the small proportion of patients who needed to re-apply imiquimod after wart recurrence.
  • [MeSH-major] Aminoquinolines / administration & dosage. Condylomata Acuminata / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Ointments / administration & dosage. Recurrence. Treatment Outcome. Vaginal Creams, Foams, and Jellies

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065134.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; 0 / Vaginal Creams, Foams, and Jellies; P1QW714R7M / imiquimod
  •  go-up   go-down


79. Das I, Saha T: Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma. Nutrition; 2009 Apr;25(4):459-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma.
  • Lipid peroxide plays a detrimental role in all cancers including skin carcinogenesis.
  • Garlic, a phytochemical, has acquired a special position in the folklore of many cultures as a formidable prophylactic and therapeutic medicinal agent.
  • In this report, we pursue the chemopreventive effect of aqueous garlic on skin carcinogenesis.
  • METHODS: "Swiss albino mice" were divided into five groups depending on the combination of skin cancer-inducing 7,12-dimethylbenz[a]anthracene and garlic treatments.
  • Histology of the affected skin and biochemical assays for lipid peroxide, catalase, superoxide dismutase, glutathione-S-transferase, and glutathione peroxidase were performed to demonstrate the effect of garlic in mice.
  • Immunoblotting was performed with cyclo-oxygenase-2, p53, and caspase-3 to demonstrate expressions of the respective proteins in skin lysates.
  • The best chemopreventive action of garlic was observed in mice in which garlic treatment was performed before and after the induction of skin carcinogenesis.
  • Garlic ingestion delayed formation of skin papillomas in animals and simultaneously decreased the size and number of papillomas, which was also reflected in the skin histology of the mice treated.
  • CONCLUSION: The protective effects against skin cancer elicited by garlic in mice are believed to be due at least in part to the induction cellular defense systems.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Antioxidants / metabolism. Garlic. Lipid Peroxidation / drug effects. Plant Extracts / pharmacology. Skin / drug effects. Skin Neoplasms / prevention & control
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / adverse effects. Animals. Benz(a)Anthracenes. Biomarkers / metabolism. Body Weight / drug effects. Carcinogens. Caspase 3 / metabolism. Cyclooxygenase 2 / metabolism. Female. Humans. Mice. Papilloma / drug therapy. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084378.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Benz(a)Anthracenes; 0 / Biomarkers; 0 / Carcinogens; 0 / Plant Extracts; 0 / Tumor Suppressor Protein p53; 2564-65-0 / 7,12-dihydroxymethylbenz(a)anthracene; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


80. Gonçalves MA, Burattini MN, Donadi EA, Massad E: Risk factors associated with genital warts in HIV-positive Brazilian women. Tumori; 2003 Jan-Feb;89(1):9-15
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were submitted to colposcopy, smear cytology, directed biopsy, and HPV-DNA detection.
  • c) drug addiction (OR, 2.38; CI, 1.09-5.19), especially in crack users (OR, 5.34; CI, 1.64-17.41);.
  • e) cervical infection caused by only one HPV type (OR, 2.77; CI 1.06-7.20);.
  • f) perianal HPV infection (OR, 2.30; CI, 0.70-7.56), associated with negative results for undetermined risk HPV (OR, 8.41; P = 0.04); and g) no antiretroviral therapy (OR, 3.41; P = 0.07).
  • CONCLUSIONS: Evaluation of behavioral risk factors associated with a genital wart history is an important tool to prevent and reduce persistent HPV infection, and consequently genital cancer precursors in HIV infected women.
  • [MeSH-minor] Adult. Age Factors. Brazil / epidemiology. Coitus. Female. Humans. Odds Ratio. Papillomavirus Infections / complications. Risk Factors. Smoking. Substance-Related Disorders / complications. Tumor Virus Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12729354.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Babu BH, Shylesh BS, Padikkala J: Tumour reducing and anticarcinogenic activity of Acanthus ilicifolius in mice. J Ethnopharmacol; 2002 Jan;79(1):27-33
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alcoholic extract of Acanthus ilicifolius (250,500 mg/kg b wt) was found to be effective against tumour progression and carcinogen induced skin papilloma formation in mice.
  • The extract also significantly delayed the onset of dimethylbenzanthrazene DMBA/Croton oil induced skin papilloma in mice in a dose dependent manner.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Papilloma / drug therapy. Plant Extracts / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Animals. Carcinogens / toxicity. Male. Mice. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11744292.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Plant Extracts; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


82. Das I, Das S, Saha T: Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: A histopathological study. Acta Histochem; 2010 Jul;112(4):317-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: A histopathological study.
  • Our aim in this study was to investigate the chemopreventive effect of aqueous saffron on chemically induced skin carcinogenesis using a histopathological approach.
  • Groups A, B, C and CC mice received three topical applications of 7,12 dimethylbenz[a]anthracene (DMBA) followed by croton oil on shaven dorsal skin for 8 weeks.
  • NC mice received topical skin applications of the vehicle, acetone, only.
  • The activities of antioxidant enzymes glutathione-S transferase (GST), glutathione peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD) in liver tissue samples taken at 0, 6, 10 and 12 weeks from all groups were assessed.
  • Standard histological examination of skin demonstrated a beneficial action of saffron in mice where saffron treatments were given both before and after the induction of skin carcinogenesis.
  • Saffron ingestion inhibited the formation of skin papillomas in animals and simultaneously reduced their size.
  • In conclusion, saffron inhibits DMBA-induced skin carcinoma in mice when treated early.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Crocus / chemistry. Oxidative Stress / drug effects. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Female. Mice. Papilloma / drug therapy. Papilloma / metabolism. Papilloma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19328523.001).
  • [ISSN] 1618-0372
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Plant Extracts; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


83. Fit KE, Williams PC: Use of histamine2-antagonists for the treatment of verruca vulgaris. Ann Pharmacother; 2007 Jul;41(7):1222-6
Hazardous Substances Data Bank. CIMETIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of histamine2-antagonists for the treatment of verruca vulgaris.
  • OBJECTIVE: To review the evidence for histamine2 (H2)-antagonists in the treatment of common warts.
  • The other retrieved citations were not evaluated due to their design (case reports or case series) and/or focus on specific wart subtypes, not common warts.
  • DATA SYNTHESIS: The use of H2-antagonists in the treatment of common warts is not associated with significant improvements in resolution rates.
  • Current data do not support the use of H2-antagonists for the treatment of common warts.
  • [MeSH-major] Histamine H2 Antagonists / therapeutic use. Warts / drug therapy
  • [MeSH-minor] Cimetidine / pharmacology. Cimetidine / therapeutic use. Humans. Randomized Controlled Trials as Topic. Receptors, Histamine / metabolism

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535844.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Receptors, Histamine; 80061L1WGD / Cimetidine
  • [Number-of-references] 25
  •  go-up   go-down


84. Gilson RJ, Ross J, Maw R, Rowen D, Sonnex C, Lacey CJ: A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts. Sex Transm Infect; 2009 Dec;85(7):514-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts.
  • OBJECTIVES: To compare the efficacy and safety of combination therapy with cryotherapy and podophyllotoxin 0.15% cream versus cryotherapy alone in the treatment of anogenital warts.
  • Further treatment from week 12 to 24 was discretionary.
  • RESULTS: 70 patients per group were randomly assigned and started treatment; 101 first-episode warts, 91 male.
  • No treatment-related serious adverse events were reported.
  • At week 4, wart clearance was higher in men (p = 0.001) and those with a past history of warts (p = 0.009), but these differences were not detected at week 12.
  • CONCLUSIONS: Initial combination therapy with podophyllotoxin/cryotherapy was well tolerated and may have resulted in earlier clearance in some patients, compared with cryotherapy alone; however, overall differences in clearance rates were not statistically significant.
  • [MeSH-major] Antiviral Agents / administration & dosage. Anus Diseases / drug therapy. Condylomata Acuminata / drug therapy. Cryotherapy / methods. Podophyllotoxin / administration & dosage. Urologic Diseases / drug therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Double-Blind Method. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Ointments. Recurrence. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700413.001).
  • [ISSN] 1472-3263
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Ointments; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


85. Agius E, Mooney JM, Bezzina AC, Yu RC: Dermojet delivery of bleomycin for the treatment of recalcitrant plantar warts. J Dermatolog Treat; 2006;17(2):112-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermojet delivery of bleomycin for the treatment of recalcitrant plantar warts.
  • When bleomycin is injected with a needle and syringe, it is difficult to prevent the bleomycin from infiltrating the dermis adjacent to the wart, producing unnecessary acute pain, persistent pain, and potential sloughing of normal adjacent skin.
  • CONCLUSIONS: This study assesses therapeutic efficacy of bleomycin delivered by dermojet in solely recalcitrant plantar warts.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Foot Diseases / drug therapy. Warts / drug therapy
  • [MeSH-minor] Humans. Injections, Intralesional / instrumentation. Prospective Studies. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766336.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


86. Dave S, Dkhar HK, Singh MP, Gupta G, Chandra V, Mahajan S, Gupta P: Hexafluoroisopropanol-induced helix-sheet transition of stem bromelain: correlation to function. Int J Biochem Cell Biol; 2010 Jun;42(6):938-47
Hazardous Substances Data Bank. BROMELAINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem bromelain is a proteolytic phytoprotein with a variety of therapeutic effects.
  • Studies using circular dichroism, fluorescence emission spectroscopy, binding of the hydrophobic dye 1-anilino-8-naphthalene sulfonic acid and mass spectrometry indicate that treatment with 10-30% hexafluoroisopropanol induces the partially folded intermediate to adopt much of the native protein's secondary structure, but only a rudimentary tertiary structure, characteristic of the molten globule state.
  • The nonnative form also showed better antitumorigenic properties, as evaluated using an induced two-stage mouse skin papilloma model.
  • This study demonstrates that hexafluoroisopropanol can induce a conformational change in stem bromelain to a form with potentially useful therapeutic properties different from those of the native protein.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bromelains / pharmacology. Fibroblasts / drug effects. Papilloma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] 3T3 Cells. Animals. Apoptosis / drug effects. Cell Proliferation / drug effects. Circular Dichroism. Female. Hydrogen-Ion Concentration. Mice. Mice, Inbred BALB C. Propanols / chemistry. Protein Structure, Secondary. Quantitative Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20156582.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Propanols; 9001-00-7 / Bromelains; 920-66-1 / hexafluoroisopropanol; EC 3.4.22.32 / stem bromelain
  •  go-up   go-down


87. Berman B, Ricotti CA Jr, Cazzaniga A, Davis SC: Determination of the area of skin capable of being covered by the application of 250 mg of 5% imiquimod cream. Dermatol Surg; 2004 May;30(5):784-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of the area of skin capable of being covered by the application of 250 mg of 5% imiquimod cream.
  • BACKGROUND: Five percent imiquimod cream is FDA-approved for the treatment of genital and perianal warts and actinic Keratosis.
  • The manufacturer recommends that a single sachet containing 250 mg of 5% imiquimod cream (12.5 mg of imiquimod) is adequate for a single use and is sufficient to cover a wart area of up to 20 cm(2).
  • OBJECTIVE: To determine the maximal area of skin that can be evenly covered by 250 mg of 5% imiquimod cream that is contained in one single-use sachet.
  • RESULTS: The average area obtained on the pig skin was 196 cm(2).
  • CONCLUSION: We have found that one sachet of 250 mg of 5% imiquimod cream can be applied to an area of skin up to 386 cm(2).
  • In light of the increasing use of 5% imiquimod cream in the treatment of cutaneous diseases, such as actinic keratoses, which affect larger areas of skin than genital warts, a more efficient use of 5% imiquimod cream may make this medication a more cost-effective treatment modality.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Condylomata Acuminata / drug therapy. Keratosis / drug therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099325.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


88. Svanborg C, Agerstam H, Aronson A, Bjerkvig R, Düringer C, Fischer W, Gustafsson L, Hallgren O, Leijonhuvud I, Linse S, Mossberg AK, Nilsson H, Pettersson J, Svensson M: HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects. Adv Cancer Res; 2003;88:1-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects.
  • HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a protein-lipid complex that induces apoptosis-like death in tumor cells, but leaves fully differentiated cells unaffected.
  • This review summarizes the information on the in vivo effects of HAMLET in patients and tumor models on the tumor cell biology, and on the molecular characteristics of the complex.
  • HAMLET limits the progression of human glioblastomas in a xenograft model and removes skin papillomas in patients.
  • This broad anti-tumor activity includes >40 different lymphomas and carcinomas and apoptosis is independent of p53 or bcl-2.
  • In tumor cells HAMLET enters the cytoplasm, translocates to the perinuclear area, and enters the nuclei where it accumulates.
  • The results illustrate how protein folding variants may be beneficial, and how their formation in peripheral tissues may depend on the folding change and the availability of the lipid cofactor.
  • We propose that HAMLET should be explored as a novel approach to tumor therapy.
  • [MeSH-major] Apoptosis. Lactalbumin / therapeutic use. Oleic Acid / therapeutic use
  • [MeSH-minor] Active Transport, Cell Nucleus. Animals. Binding Sites. Calcium / metabolism. Cell Differentiation. Cytoplasm / metabolism. Dose-Response Relationship, Drug. Drug Therapy, Combination. Humans. Ions. Lipids. Neoplasm Transplantation. Protein Conformation. Protein Folding. Proto-Oncogene Proteins c-bcl-2 / metabolism. Time Factors. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism

  • Hazardous Substances Data Bank. OLEIC ACID .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12665051.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ions; 0 / Lipids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 2UMI9U37CP / Oleic Acid; 9013-90-5 / Lactalbumin; SY7Q814VUP / Calcium
  • [Number-of-references] 90
  •  go-up   go-down


89. Langley PC: A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. J Med Econ; 2010 Mar;13(1):1-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts.
  • OBJECTIVE: To evaluate the cost-effectiveness and treatment-cost impact of sinecatechins (Veregen) as first-line therapy against its principal comparator, imiquimod (Aldara), in the treatment of external genital warts (EGWs).
  • METHOD: A two-stage decision model is proposed to compare sinecatechins with its principal comparator, imiquimod, as a first-line topical therapy in the treatment of EGWs.
  • (1) trial-based estimates of average drug utilization and (2) CPT (Current Procedural Terminology) codes describing anticipated office visits and utilization of second-line ablative procedures.
  • As a modeled approach to evaluating comparative product effectiveness, the claims made reflect the structure of the model, which focuses on topical products as first-line therapy in EGW interventions and in its reliance on estimates of sustained clearance from pivotal randomized clinical trials (RCTs).
  • Sustained clearance in this context being defined as the proportion of patients who report initial wart clearance over the RCT period corrected for subsequent recurrence.
  • RESULTS: As first-line therapy, sinecatechins dominates imiquimod as a lower cost treatment with a higher sustained clearance rate (51.9 vs. 40.6%).
  • First-line average cost of treatment with sinecatechins is $774 compared to imiquimod at $930.
  • Taking account of patients failing first-line therapy moving to a second-line ablative therapy yields an average cost of treatment for patients initiated to sinecatechins of $943 and $1,138 for those initiated to imiquimod.
  • A sensitivity assessment confirmed the position of sinecatechins within the decision-model framework.
  • CONCLUSION: Sinecatechins yields a lower cost of treatment compared to imiquimod in the treatment of EGW.
  • This conclusion should be qualified by the limitations of the decision framework within which the assessment has been made.
  • The model focuses on topical preparations as first-line therapies, with estimates of sustained clearance taken from pivotal RCTs.
  • Treatment cost estimates are generated independently, but reflect current product and ancillary costs.
  • [MeSH-minor] Confidence Intervals. Cost-Benefit Analysis. Decision Support Techniques. Drug Utilization. Humans. Models, Economic. Treatment Outcome. United States

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929627.001).
  • [ISSN] 1941-837X
  • [Journal-full-title] Journal of medical economics
  • [ISO-abbreviation] J Med Econ
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Plant Extracts; 8R1V1STN48 / Catechin; 99011-02-6 / imiquimod
  •  go-up   go-down


90. Stender IM, Borgbjerg FM, Villumsen J, Lock-Andersen J, Wulf HC: Pain induced by photodynamic therapy of warts. Photodermatol Photoimmunol Photomed; 2006 Dec;22(6):304-9
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain induced by photodynamic therapy of warts.
  • BACKGROUND: Photodynamic therapy with topical 5-aminolevulinic acid (ALA), followed by irradiation with red light (ALA-PDT), is used for non-melanoma skin cancer and other dermatological diseases.
  • Pain during and after light exposure is a well-known adverse advent that may be a limiting factor for treatment, particularly, in viral warts.
  • METHODS: To assess the pain induced by ALA-PDT, we asked 45 patients enrolled in a randomized, placebo-controlled trial with six consecutive ALA- and placebo-PDT treatments for recalcitrant foot and hand warts to fill in questionnaires about pain immediately and 24 h after each treatment.
  • RESULTS: Immediately and 24 h after each of the six treatments, pain intensity was significantly higher in warts treated with ALA-PDT than in warts treated with placebo-PDT (P<0.028).
  • Severe or unbearable pain was reported from a median of 17% (6-31%) of the ALA -treated warts and from a median of 2% (0-15%) from the placebo-treated warts immediately after the treatments.
  • With increasing treatments, no significant change in pain intensity was observed and no significant relation was found between the pain intensity and the relative change in wart area.
  • [MeSH-major] Foot Dermatoses / drug therapy. Hand Dermatoses / drug therapy. Pain, Postoperative / prevention & control. Photochemotherapy / adverse effects. Warts / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aminolevulinic Acid / administration & dosage. Female. Humans. Light. Male. Middle Aged. Pain Measurement. Photosensitizing Agents / administration & dosage. Surveys and Questionnaires. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100738.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


91. Jang HS, Oh CK, Cha JH, Cho SH, Kwon KS: Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics. J Am Acad Dermatol; 2001 Apr;44(4):652-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Confluent and reticulated papillomatosis (CRP) is a relatively rare disorder manifested by persistent papules that are confluent in the center and reticulated at the periphery with a characteristic distribution.
  • Case 5 reports a 24-year-old man who received oral azithromycin, 500 mg daily 3 times per week for 3 weeks.
  • Complete clearing after treatment with antibiotics raises the possibility that CRP is triggered by a bacterial infection and that antibiotics are the treatment of choice for CRP.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Papilloma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11260541.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  • [Number-of-references] 18
  •  go-up   go-down


92. Schwartzberg JB, Schwartzberg HA: Response of confluent and reticulate papillomatosis of Gougerot and Carteaud to topical tretinoin. Cutis; 2000 Oct;66(4):291-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Confluent and reticulate papillomatosis (CRP) of Gougerot and Carteaud is a rare cutaneous disorder characterized by persistent, usually asymptomatic, dark papules and plaques centrally located on the back, intermammary, and epigastric areas.
  • Many different treatments, with varying success rates, have been attempted.
  • The only difficulty with therapy is applying the tretinoin to the back, which sometimes necessitates a second person.
  • However, if this situation can be overcome, topical tretinoin provides an effective, safe alternative to systemic therapies.
  • Response to tretinoin provides support that CRP is a disorder of keratinization.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Papilloma / drug therapy. Skin Neoplasms / drug therapy. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109153.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


93. Wilson WR, Hashemiyoon R, Hawrych A: Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report. Ear Nose Throat J; 2000 Apr;79(4):236-8, 240
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report.
  • This is a preliminary report of an ongoing study to test the efficacy of intralesional injections of the antiviral drug cidofovir in adults with recurrent laryngeal papillomas in whom multiple other treatments have previously failed.
  • The approximate volume injected into each wart was 0.2 to 0.5 ml.
  • Biopsies of the lesion sites were obtained at the initiation and completion of therapy.
  • No other treatment was given.
  • Resolution of lesions was monitored by videolaryngoscopy and still photography 1 to 2 weeks after each treatment.
  • In time, the lesions resolved in all three patients, although all three later experienced a minor recurrence.
  • We conclude that intralesional cidofovir appears to be a promising new treatment for controlling--and perhaps at higher dosages curing--refractory laryngeal papillomas, while causing little or no injury to laryngeal structures.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adult. Clinical Protocols. Humans. Injections, Intralesional. Male. Middle Aged. Papillomaviridae / isolation & purification. Recurrence. Retreatment. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10786384.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


94. Singh RP, Tyagi AK, Zhao J, Agarwal R: Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis; 2002 Mar;23(3):499-510
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.
  • This study reports in vivo therapeutic efficacy of silymarin against skin tumors with mechanistic rationale.
  • 7,12-Dimethylbenz[a]anthracene-12-O-tetradecanoyl-phorbol-13-acetate (DMBA-TPA)-induced established skin papilloma (tumor)-bearing SENCAR mice were fed with 0.5% silymarin in AIN-93M-purified diet (w/w), and both tumor growth and regression were monitored during 5 weeks of feeding regimen.
  • Silymarin feeding significantly inhibited (74%, P < 0.01) tumor growth and also caused regression (43%, P < 0.01) of established tumors.
  • Skin tumor growth inhibition and regression by silymarin were also accompanied by a strong decrease (P < 0.001) in phospho-ERK1/2 levels in tumors from silymarin-fed mice compared with controls.
  • In the studies evaluating bioavailability and physiologically achievable level of silymarin (as silibinin) in plasma, skin tumor, skin, liver, lung, mammary gland and spleen, we found 10, 6.5, 3.1, 13.7, 7.7, 5.9 and 4.4 microg silibinin/ml plasma or per gram tissue, respectively.
  • In an attempt to translate these findings to human skin cancer and to establish biological significance of physiologically achievable level, effect of plasma concentration of silibinin was next examined in human epidermoid carcinoma A431 cells.
  • Silibinin treatment of cells in culture at 12.5, 25 (plasma level) and 50 microM doses resulted in 30-74% (P < 0.01-0.001) growth inhibition and 7-42% death of A431 cells in a dose- and time-dependent manner; apoptosis was identified as a cell death response by silibinin.
  • Similar silibinin treatments also resulted in a significant decrease in phospho-mitogen-activated protein kinase/extracellular signal-regulated protein kinase 1/2 (MAPK/ERK1/2) levels, but an up-regulation of stress-activated protein kinase/jun NH(2)-terminal kinase (SAPK/JNK1/2) and p38 mitogen-activated protein kinase (p38 MAPK) activation in A431 cells.
  • These data suggest that silymarin and/or its major active constituent silibinin could be an effective agent for both prevention and intervention of human skin cancer.
  • [MeSH-major] Apoptosis / drug effects. Mitogen-Activated Protein Kinases / metabolism. Silymarin / pharmacology. Silymarin / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Division / drug effects. Enzyme Activation / drug effects. Female. Humans. JNK Mitogen-Activated Protein Kinases. MAP Kinase Kinase 1. Mice. Mice, Inbred SENCAR. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinase Kinases / metabolism. Organ Specificity. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / metabolism. Time Factors. Tumor Cells, Cultured


95. Agrawal RC, Pandey S: Evaluation of anticarcinogenic and antimutagenic potential of Bauhinia variegata extract in Swiss albino mice. Asian Pac J Cancer Prev; 2009;10(5):913-6
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: To evaluate the anticarcinogenicity and antimutagenicity of Kachanar extract a skin carcinogenesis and melanoma tumour model was used, along with micronucleus and chromosomal aberration tests, in Swiss albino mice.
  • RESULTS: In the skin papilloma model, significant prevention, with delayed appearance and reduction in the cumulative no. of papillomas was observed in the DMBA + Kachanar + croton oil treated group as compared to the DMBA + Croton Oil group.
  • [MeSH-major] Antimutagenic Agents / pharmacology. Antineoplastic Agents / pharmacology. Bauhinia / chemistry. Melanoma, Experimental / drug therapy. Papilloma / drug therapy. Phytotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Animals. Carcinogens / toxicity. Chromosome Aberrations / drug effects. Croton Oil. Cyclophosphamide / pharmacology. Female. Male. Mice. Mice, Inbred C57BL. Micronuclei, Chromosome-Defective / drug effects. Plant Extracts / pharmacology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104989.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antimutagenic Agents; 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Plant Extracts; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 8001-28-3 / Croton Oil; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


96. Geetha BS, Latha PG, Remani P: Evaluation of Elephantopus scaber on the inhibition of chemical carcinogenesis and tumor development in mice. Pharm Biol; 2010 Mar;48(3):342-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Elephantopus scaber on the inhibition of chemical carcinogenesis and tumor development in mice.
  • The effect of the active fraction of Elephantopus scaber L. (Asteraceae) (ES) on skin papillomas induced by 7,12-dimethylbenz(a)anthracene (DMBA) as an initiator and croton oil as promoter was studied in mice.
  • The active fraction of E. scaber (100 mg/kg) on topical application delayed the onset of papilloma formation and reduced the mean number of papillomas and the mean weight of papillomas per mouse.
  • The intraperitoneal administration of the active fraction of E. scaber also had a significant effect on subcutaneous injection of 20-methylcholanthrene (20-MCA)-induced soft tissue sarcomas in mice.
  • It inhibited the incidence of sarcomas and reduced the tumor diameter compared to MCA-treated control animals.
  • The subcutaneous administration of the active fraction of E. scaber significantly inhibited the growth of subcutaneously transplanted DLA and EAC solid tumors, delayed the onset of tumor formation, and increased the life span of tumor bearing mice.
  • The present study thus indicates the tumor inhibitory activity of the active fraction of E. scaber against chemically induced tumors and its ability to inhibit the development of solid tumors.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / prevention & control. Phytotherapy. Plant Extracts / therapeutic use. Vernonia / chemistry
  • [MeSH-minor] Administration, Cutaneous. Animals. Drug Screening Assays, Antitumor. Injections, Intraperitoneal. Male. Mice. Neoplasm Transplantation. Time Factors. Tumor Burden / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645824.001).
  • [ISSN] 1744-5116
  • [Journal-full-title] Pharmaceutical biology
  • [ISO-abbreviation] Pharm Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


97. Babu BH, Jayram HN, Nair MG, Ajaikumar KB, Padikkala J: Free radical scavenging, antitumor and anticarcinogenic activity of gossypin. J Exp Clin Cancer Res; 2003 Dec;22(4):581-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It reduces the tumor burden in solid tumor harboring animals (p < 0.001) and effectively inhibits the formation of new blood vessels on tumor mass.
  • 20 mg/kg b.wt of gossypin increase the life span of ascites tumor harboring animals (100%) and (164.7%) respectively by oral and intraperitoneal administration of the drug.
  • Gossypin reduced the incidence of papilloma formation and papilloma/mouse in DMBA/ croton oil induced skin papilloma.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antioxidants / therapeutic use. Flavonoids / therapeutic use. Free Radical Scavengers / therapeutic use. Free Radicals / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Inhibitory Concentration 50. Mice. Papilloma / blood supply. Papilloma / chemically induced. Papilloma / drug therapy. Papilloma / pathology. Rats. Survival Rate

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053300.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Free Radicals; A3Q367XWX9 / gossypin
  •  go-up   go-down


98. Ahmad N, Kalka K, Mukhtar H: In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene; 2001 Apr 26;20(18):2314-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy.
  • PDT, a new therapeutic procedure for the management of many malignant conditions including skin cancer, involves the administration of a photosensitizing compound followed by illumination of the lesion with visible light.
  • Here, we investigated the involvement of EGFR-pathway during antiproliferative responses of Pc4-PDT in A431 cells and during ablation of murine skin papillomas.
  • Pc4-PDT of A431 cells was found to result in a time-dependent down-modulation of the protein expression and phosphorylation of EGFR and Shc (an immediate downstream molecule in EGFR-pathway), during progressive increase in apoptotic response.
  • To establish the relevance of these in vitro findings to in vivo situations, we subjected chemically- as well as ultraviolet B radiation-induced squamous papillomas in SENCAR and SKH-1 hairless mice, respectively, to Pc4-PDT, and assessed its effect on EGFR-pathway during ablation of these tumors.
  • Pc4-PDT was found to result in a time-dependent: (i) inhibition of protein expressions of EGFR; and (ii) tyrosine phosphorylation of EGFR and Shc; and (iii) induction of apoptosis, during the regression of these tumors.
  • It is tempting to speculate that inhibitors of EGFR could enhance the therapeutic efficacy of PDT.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / physiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cell Cycle / drug effects. Cell Cycle / physiology. Humans. Immunoblotting. Indoles / pharmacology. Mice. Mice, Hairless. Mice, Inbred SENCAR. Photosensitizing Agents / pharmacology. Skin Neoplasms / drug therapy. Skin Neoplasms / enzymology. Skin Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11402326.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 48735; United States / NIAMS NIH HHS / AR / P30 AR 39750; United States / NCI NIH HHS / CA / P30 CA 43703; United States / NCI NIH HHS / CA / R01 CA 51802
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Photosensitizing Agents; 0 / phthalocyanine Pc 4; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


99. Chadha NK, James A: Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev; 2010;(1):CD005053
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant antiviral therapy for recurrent respiratory papillomatosis.
  • BACKGROUND: This is an update of a Cochrane Review originally published in Issue 4, 2005 of The Cochrane Library.Recurrent respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the upper airway.
  • Treatment usually involves repeated surgical debulking of the papillomata.
  • OBJECTIVES: To assess the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children and adults.
  • MAIN RESULTS: The included study was a single-institution, randomised, double-blind, placebo-controlled trial of intralesional cidofovir administered at the time of surgical debulking.
  • Both groups showed a significant reduction in disease extent (as assessed at the time of surgery using the Derkay Scoring System), but no significant change in health-related quality of life.
  • AUTHORS' CONCLUSIONS: There is insufficient evidence to support the efficacy of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children or adults.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Airway Obstruction / drug therapy. Airway Obstruction / virology. Chemotherapy, Adjuvant. Child. Humans. Recurrence

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;12:CD005053 [23235619.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(4):CD005053 [16235390.001]
  • (PMID = 20091568.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 27
  •  go-up   go-down


100. Fife KH, Ferenczy A, Douglas JM Jr, Brown DR, Smith M, Owens ML, HPV Study Group: Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis; 2001 Apr;28(4):226-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
  • BACKGROUND: Medical therapy for genital warts remains suboptimal.
  • The topical interferon and cytokine inducer, imiquimod, has been proved effective for the treatment of external genital and perianal warts, but there is a substantial difference in the response rates between men and women.
  • When 5% imiquimod cream is applied three times a week up to 16 weeks, approximately two thirds of women treated with imiquimod achieve complete clearance of genital warts, whereas only about one third of men clear completely.
  • GOAL: This study was undertaken to determine whether more frequent application of topical imiquimod cream would improve the rate of genital wart clearance in men.
  • STUDY DESIGN: A randomized treatment trial involving adult men with biopsy-proven genital warts was conducted at nine centers in the United States and Canada using four different application frequencies.
  • RESULTS: Complete clearance rates during the 16-week treatment period were as follows for the different imiquimod treatment frequencies: three times a week (35 %), once daily (28 %), twice daily (24%), and three times a day (27%)(P = 0.88).
  • The four treatment groups all showed comparable reductions in the total lesion area, with a median of more than a 90% reduction in the lesion area by the end of treatment.
  • There was a significant increase in the incidence and severity of local skin reactions including erythema, vesicle formation, ulceration, and excoriation as the dosing frequency increased from three times a week to three times a day.
  • CONCLUSIONS: In this study, the optimal dosage regimen was the approved three times a week regimen.
  • More frequent application (up to three times a day) did not improve clearance and was associated with an increase in local adverse events.
  • [MeSH-major] Aminoquinolines / therapeutic use. Condylomata Acuminata / drug therapy. Interferon Inducers / therapeutic use
  • [MeSH-minor] Adult. Aged. Antibodies, Viral / blood. Dose-Response Relationship, Drug. Drug Administration Schedule. Erythema / chemically induced. Humans. Male. Middle Aged. Neopterin / blood. Papillomaviridae / immunology. Ulcer / chemically induced

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11318254.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antibodies, Viral; 0 / Interferon Inducers; 670-65-5 / Neopterin; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement